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I. INTRODUCTION 
 
 
 
 
I.1 STRUCTURAL BIOLOGY 
Proteins are one of the four main classes of molecules, along with carbohydrates, fats, 
and nucleic acids, that underlie all life, since they are responsible of most cellular function. 
The massive advances in genomics research over the past few years have now led to a 
renewed focus on protein structure and function.  
Genome sequencing projects have provided a list of proteins contained in the cell. This list is 
still incomplete, as it does not always capture variants like alternative spliced forms or post-
translational modifications. Nevertheless, it provides the scaffold onto which most functions 
lie. 
The successes of high-throughput approach in genomics (DNA sequencing, DNA 
microarrays) have inspired similar initiatives in protein science, with high-throughput 
programmes for 3D structure determination1. 
Structural biology has emerged as a powerful approach for defining the functions of proteins; 
this capacity is based on the observation that the evolutionary constraints for three-
dimensional structures of proteins are higher than for sequences2,3.There are many cases of 
distantly related homologues assignable from shared structures with no recognizable 
relationship between their sequences. Many algorithms have been implemented for alignment 
by structural analogy. 
The strong predictive power of structure in functional annotation has resulted in the rapid 
growth of the new field of structural genomics (SG) (or structural proteomics)4 and to the 
rapid development of novel high-throughput technologies4,5. In addition to expediting 
functional characterization of gene products, SG initiatives also provide a comprehensive 
view of the protein structure universe, by determining the structures of representative proteins 
from every protein fold family6. In the same time, bioinformatics collects data on sequences, 
structures, and functions, and studies the correspondences between them. 
Over the past 10 years, several international structural genomics initiatives have been funded 
with diverse approaches7-10. For instance, the Protein Structure Initiative (PSI) in the United 
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States, has been devoted to the study of the complex relationships between the evolution of 
the function of proteins with respect to the evolution of their sequence and structure.  
Both the number of sequences and protein families are still growing at an exponential rate, but 
domain families are 10-fold fewer (<10 000) than the number of protein families, for this 
reason the structural genomics initiatives consider domains as the fundamental unit of both 
protein structure and evolution. For instance, the SCOP database has as its basis individual 
domains of proteins. Sets of domains are grouped into families of homologues, for which the 
similarities in structure, sequence, and sometimes function, imply a common evolutionary 
origin [http://scop.mrc-lmb.cam.ac.uk/scop /index.html]. 
Like most sequence-based methods, these structure-based methods proceed by searching for 
homologues and do not permit unambiguous assignment of a precise function: even closely 
related proteins can have different functions11, conversely, non-homologous proteins may 
have similar functions, moreover there are numerous examples of proteins with multiple 
functions. 
For instance, multi-domain proteins present particular problems for functional annotation, 
because each domain may possess independent functions, modulate one another’s function, or 
act in concert to provide a single function. 
For these limits of structure-based methods, a functional genomic approach,  making use of 
contextual information and intergenomic comparisons, is useful to predict a protein function 
on the basis of inferences from genomic contexts and protein interaction patterns12-15. 
Functional genomics can use different approaches for predictions of  protein functions, 
deriving information from relationship between non-homologous proteins16: 
− Gene fusion. A composite gene in one genome may correspond to separate genes in 
other genomes. For instance, the proportion of multidomains protein is higher in eukaryota 
with respect to prokaryota17. 
− Local gene context. Analyse co-regulated and co-transcribed components of a 
pathway. (In bacteria, genes in a single operon are usually functionally linked). 
− Interaction patterns. The network of interactions reveals the function of a protein. 
− Phylogenetic profiles. Proteins in a common structural complex or pathway are 
functionally linked and expected to co-evolve18.  
Comparison of the flexibilities of homologous proteins across species suggested that, as the 
species gets more complex, its proteins become more flexible. In fact the  number of genes in 
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the human genome is fewer than that of some lower organisms but our genome is more 
flexible and functionally more complex19.  
In contrast to the classical view of structured proteins, the concept of intrinsically disordered 
regions has recently emerged20-25. Disordered regions are protein segments that does not 
completely fold and remains flexible and unordered, existing in a continuum of conformations 
from the less to the more structured states26.  
The importance of intrinsically disordered proteins rely on their involvement in a broad range 
of functions27. Moreover, knowledge of the folded and denatured states under different 
conditions, can help in the comprehension of protein folding. Genomic analysis of disordered 
proteins indicates that the proportion of the genome encoding intrinsically unstructured 
proteins increases with the complexity of organisms28: computational predictions estimate that 
proteomes of archaea and bacteria comprise only a small fraction of intrinsically disordered 
proteins (about 2–4%), while eukaryotic proteomes include a large fraction (about 33%) of 
long regions that are natively disordered and thus do not adopt a fixed structure29. Disordered 
regions of proteins have been shown to have key physiological roles, for example, are 
involved as communicators in many cellular signalling pathways30-32.  
Disordered functional proteins provide evidence that the function of a protein and its 
properties are not only decided by its static folded three-dimensional structure; they are 
determined by the distribution and redistribution of the conformational substates33. 
Intrinsically disordered proteins can be broadly classified into two major groups: those that 
are fully disordered throughout their length (often called natively unfolded proteins) and those 
that have extensive (>30–40 residues) regions that are disordered and embedded in an 
otherwise folded protein. Natively unfolded proteins can be further subdivided into two 
groups, those with no ordered secondary structure and those with some secondary structure; 
the latter resemble molten globules and lack tertiary structure. 
One distinction in the amino acid sequences of natively unfolded proteins has been suggested 
in the literature, like the presence of numerous uncompensated charged groups (often 
negative) at neutral pH, arising from the extreme pI values in such proteins. A low content of 
hydrophobic amino acid residues has been also noted for several natively unfolded proteins. 
Moreover, disordered regions of proteins are characterized by low sequence complexity, high 
flexibility and amino acid compositional bias: compared to sequences of ordered proteins, 
intrinsically disordered segments and proteins have significantly higher levels of certain 
amino acids (E, K, R, G, Q, S and P) and lower levels of others (I, L, V, W, F, Y, C and N). 
For these features, long disordered polypeptide sequences can be predicted successfully from 
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amino acid sequence34.  For instance, FoldIndex is a program that estimates the local and 
general probability of the provided sequence to fold [http://bip.weizmann.ac.il/fldbin/findex]. 
Recent studies have identified a natively folded protein that break the Anfinsen’s hypothesis: 
“a polypeptide achieves its biologically active, native state by descending to the most 
thermodynamically stable configuration, which corresponds to one of a few thousand unique 
folds, with varying amounts of local flexibility”. The human chemokine lymphotactin (Ltn) 
adopts two distinct folds at equilibrium in physiological conditions, and interconversion 
between the conformers involves almost complete restructuring of its hydrogen bond network 
and other stabilizing interactions, in contrast to other cases of different conformers that share 
a large common substructure during interconversion35,36. 
Because each Ltn conformer displays only one of the two functional properties essential for 
its activity in vivo (Receptor activation and Glycosaminoglycans binding), the conformational 
equilibrium is likely to be essential for the biological activity of lymphotactin and could 
represent a novel regulatory mechanism for proteins functions. 
Therefore, it is clear that proteins with large unstructured regions and natively unfolded 
proteins have a very important physiologic role.  
This research project has been focused on the expression of proteins with large unstructured 
regions, which are involved in protein-protein interactions and in cell signalling. 
 
I.2. PROTEIN-PROTEIN INTERACTIONS 
A practical way to understand protein functions is the identification of binding 
partners. Valuable information on cellular pathways can be obtained by investigating protein-
protein interaction. These data are also helpful in drug design and to evaluate the role of 
mutations, which are often clustered in binding sites37.  
The recent increase in the number of protein structures, the additional experimental results of 
protein-protein interactions indicate that some proteins are centrally connected, whereas 
others are at the edges of the map38.   
The centrally connected proteins may interact with a large number of partners and usually act 
as linkers of cellular processes, as regulatory elements in the organization of higher order 
protein interactions networks. Such proteins are usually  those that perform the same function 
for many partners (phosphatases, kinases, transporters,…). The interface of such proteins 
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preferentially consists of  α-helices. The capability to interact with a broad range of partner 
proteins is related to their  higher content of repeat domains. These domains are easy to make 
(by duplication) and offer an opportunity to divergently evolve. At the same time, there is 
evidence that proteins whose function requires more specific interactions evolve slowly. 
A large fraction of cellular proteins that play roles in cell-cycle control, signal transduction, 
transcriptional and translational regulation, and large macromolecular complexes, are 
estimated to be natively disordered39. Their native conformation can be stabilized upon 
binding. The global fold of disordered proteins does not change upon binding to different 
partners; however, local conformational variability can be observed, complicating the 
predictions of protein interactions. Upon binding, the equilibrium shifts in favour of the 
complex formation, further driving the reaction. As binding and folding are similar processes 
with similar underlying principles, this principle applies to disordered molecules in binding 
and to unstable, conformationally fluctuating building blocks in folding.  
Protein-protein interactions are largely driven by the hydrophobic effect however hydrogen 
bonds, electrostatic interactions, and covalent bonds are also important40. 
The Gibbs free energy upon complex formation (binding free energy) can be determined 
directly from the equilibrium constant of the reaction (usually denoted as Ka and Kd, for 
association or dissociation constants). The equilibrium constants is function of the 
concentrations of both the free proteins and the complex at thermodynamic equilibrium.  
The range of Kd values observed in biologically relevant processes is extremely wide and can 
span over twelve orders of magnitude. Weak protein-protein interactions, especially those 
with Kd>10-4 M, have been poorly characterized, despite they might be crucial for mediating 
many important cellular events41. 
An enormous number of enzymes, carrier proteins, scaffolding proteins, transcriptional 
regulatory factors, etc. function as oligomers. 
Oligomerization and function in oligomeric proteins can be very finely tuned by ligand 
concentration (including ions, substrate, allosteric ligands, protons, etc.) and by protein 
concentration, influenced by expression levels, transport mechanisms or degradation rates. 
The formation of transient protein–protein complexes depends on the functional state of the 
partners. The affinities of such complexes are modulated at different levels, including 
interaction with ligands, other proteins, nucleic acids, ions such as Ca2+, and covalent 
modification, such as specific phosphorlyation or acetylation reactions. 
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The interfaces in transient complexes are generally less extensive and more polar or charged, 
moreover the surfaces of interacting proteins at their interface are not optimized, leading to 
weaker associations, with the exception of some enzyme-inhibitor complexes42. 
On the contraty, obligatory complexes are in general tighter, with a stronger hydrophobic 
effect, better packing and fewer structural water molecules between the monomers, and they 
have better shape complementarity43. 
The characterization of structural motifs and domains involved in protein-protein interactions 
is important to understand  the networks relevant for living cell and possible roles in 
diseases44.  
 
I.3. SYSTEM BIOLOGY 
Molecular biology has until now mainly focussed on individual molecules, on their 
properties as isolated entities or as complexes in very simple model systems.  
Scientific and technical advances triggered an exponential increase in the number of 3D 
structures deposited in the Protein Data Bank45,46. The number of protein complexes equally 
increased, providing thousands of different templates to model protein–protein interfaces.  
Biological molecules in living systems participate in very complex networks, including 
regulatory networks for gene expression, intracellular metabolic networks and both intra- and 
intercellular communication networks. Such networks are involved in the maintenance 
(homeostasis) as well as the differentiation of cellular systems of which we have a very 
incomplete understanding. 
Complete genomes, interaction and functional data must be integrated with 3D structures to 
build large cellular systems from their individual molecular components in order to 
understand how complex systems function and evolve. That is, scaling up from molecular 
biology to systems biology. 
The aim of systems biology is the quantitative analysis and reconstruction of  the structure 
and dynamics of cellular pathways via an in silico representation of the studied pathways, by 
an iterative process of matching experimental observations against model predictions to 
formulate new models and new experiments to test them47,47,48. 
In particular, it is important to define all of the components of the system, including the 
regulatory relationships between genes and interactions of proteins and biochemical 
pathways, and to use this knowledge to formulate a primitive model (biochemical or 
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mathematical) 49. Once the system structure is defined, system behaviour can be analysed 
further using specific genetic and/or environmental perturbations. The data generated from 
such an analysis can either be integrated with the initial model or used to refine the model, 
such that its predictions are consistent with the experimental observations. The importance of 
systems biology research rely on the identification of novel protein functions or partners and 
the understanding of mechanisms that control the state of the cells so that they can be used to 
identify potential therapeutic targets for treatment of diseases. 
 
I.4. MOLECULAR BIOLOGY 
Understanding the molecular mechanisms by which cells carry out signal transduction 
pathways and control cell homeostasis, is an important goal to increase our knowledge of 
biology and to develop specific therapies for diseases. In this thesis will be discussed proteins, 
interactions and mechanisms involving proteins responsible for intra- and extracellular 
signaling pathways.  
Our work has been focused on a group of proteins involved in intra- and extra-cellular 
signalling pathways. 
 
I.4.1. Matrix Metalloproteinases 
Matrix metalloproteinases represent a large family of 23 zinc-dependent 
endopeptidases in human, that on the basis of substrate specificity, sequence similarity, and 
domain organization, can be divided into six groups: Collagenases, Gelatinases, Stromelysins, 
Matrilysins, Membrane-Type MMPs, Other MMPs.  
The MMPs share common structural and functional elements (Fig. 1).  
Most members of the MMP family are secreted and organized into three well-conserved 
domains: an  aminoterminal propeptide; a catalytic domain; and a hemopexin-like domain at 
the carboxy-terminal50. The propeptide consists of approximately 80–90 amino acids 
containing a cysteine residue, which interacts with the catalytic zinc atom via its side chain 
thiol group. Removal of the propeptide by proteolysis results in zymogen activation, as all 
members of the MMP family are produced in a latent form. The catalytic domain contains two 
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Fig.1. Domains organization in different classes of MMPs. 
 
zinc ions and at least one calcium ion. One of the two zinc ions is structural, the other is 
essential for the proteolytic activity of MMPs and the three histidine residues that coordinate 
the catalytic zinc are conserved among all the MMPs. The hemopexin-like domain of MMPs 
is highly conserved and shows sequence similarity to the plasma protein hemopexin. The 
hemopexin-like domain has been shown to play a functional role in substrate binding and/or 
in interactions with the tissue inhibitors of metalloproteinases (TIMPs), a family of specific 
MMP protein inhibitors. In addition to these basic domains, the family of MMPs evolved into 
different subgroups by incorporating and/or deleting structural and functional domains. For 
instance, fibronectin type-II like domain in the gelatinases, transmembrane domain at the 
carboxy terminus and recognition motif (RXKR) for furin-like convertases at the end of the 
propeptide domain are characteristics of the membrane-type MMPs (MT-MMPs)51,52. 
MMPs are best known for their functions in remodeling of extracellular matrix and for their 
important roles in wound healing, angiogenesis, and invasive properties of cancer cells. 
Extracellular matrix (ECM) macromolecules are important for creating the cellular 
environments required during development and morphogenesis. Modulation of cell–matrix 
interactions and the integrity and composition of the ECM structure regulate cell proliferation, 
differentiation, and cell death.  
Since MMPs are the major group of enzymes that regulate cell–matrix composition, loss of 
MMPs activity control may result in diseases such as arthritis, cancer, atherosclerosis, 
aneurysms, nephritis, tissue ulcers, and fibrosis. Moreover, cell membrane proteins have also 
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been identified as MMP substrates, expanding the potential importance of this family to 
include direct effects on cell-cell signalling, intercellular interactions, and intracellular 
signaling. For instance, MMPs can cleave cell-cell adhesion molecules like E-cadherin, 
modulate cell-ECM interactions through processing of integrins, convert cytokines precursor 
such as protransforming growth factor-β and protumor necrosis factor-α, or release cytokines 
or growth factors like Insulin like growth factor (IGF) from ECM or carrier proteins; 
moreover cell membrane receptors such as Protease-Activated Receptors (PAR-1) can be 
processed by MMPs53,54. 
The activity of MMPs can be regulated at different levels:  
− Transcription factor binding sites in MMPs gene promoters, Histones Acetylation and 
DNA methylation regulate MMPs gene expression in response to various stimuli;  
− At the post-transcriptional level, RNA-binding proteins and microRNA can regulate 
the stability of MMPs mRNA;  
− Enzymatic activation of the precursor zymogen by cleavage of prodomain;  
− Interaction with specific ECM components;  
− Inhibition by TIMPs55.  
During tissue injury and repair, the expression levels of many MMPs are regulated by 
inflammatory cytokines such as TNF-α and IL-1. Beside cytokines, ECM components as well 
as mechanical stress can modulate MMPs expression. 
During cancer, MMPs can be expressed either by tumor cells or stromal and infiltrating 
inflammatory cells, providing evidence that the adaptative and innate immune system play an 
important role in the process of tumor progression. Indeed, upregulation of MMPs has 
traditionally been associated to tumor progression, both at the primary and secondary site, but 
recent studies reported that some host-derived MMPs have anti-tumorigenic effects56-58. 
Recent studies have also associated MMPs activation to genetic instability. One mechanism 
proposed to explain the MMPs-dependent genetic instability is associated to nuclear 
localization of MMPs. Indeed, recent studies observed MMP-2 and MMP-3 in the nuclear 
compartment and a putative nuclear localization signal was identified in their sequence, as 
well as in other MMPs59,60.  
These recent findings highlight novel pathways, representing important aspects of MMPs 
activity and functions in the cells. 
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I.4.2.  Protease-Activated Receptors 
Protease-Activated Receptors (PARs) belong to a subfamily of four G proteins-
Coupled Receptors (GPCRs) with seven transmembrane domains that acts as sensors of 
proteases in extracellular environment. PARs are activated by a unique mechanism: proteases 
activate PARs by proteolytic cleavage within the extracellular N-terminus of their receptors, 
thereby exposing a novel “cryptic” N-terminal sequence activating the receptor. 
Specific residues (about six amino acids) within this tethered ligand domain are 
believed to interact with extracellular loop 2 and other domains of the cleaved receptor, 
resulting in intra-molecular activation. This activation process is followed by coupling to G 
proteins and the triggering of a variety of downstream signal transduction pathways61 (Fig. 2).  
 
 
Fig. 2. PARs activation mechanisms by proteases. Partial sequence alignment  of 
PAR1-4 N- terminal sequences, with highlighted the tethered ligand exapeptides. 
 
Stimulation and termination of PAR-mediated signalling is regulated by several mechanisms.  
The availability of PARs at the cell surface is governed by trafficking of the receptor from 
intracellular stores, and the signaling properties depend on the presence of G proteins and G 
protein-coupled receptor kinases (GRKs) that modulate PARs activity62. PAR-1, PAR-3, and  
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PAR-4 are targets for thrombin, trypsin, or cathepsin G. In contrast, PAR-2 is resistant to 
thrombin, but can be activated by trypsin, mast cell tryptase, factor Xa, acrosin, gingipain, and 
neuronal serine proteinases. 
For PAR-1, PAR-2, and PAR-4, it is well established that short synthetic peptides [PAR-
activating peptides (PAR-APs)] designed on their proteolytically revealed tethered ligand 
sequences can serve as selective receptor agonists and some PAR-APs activate more than one 
PAR. PAR-3 on its own does not appear to signal and does not respond either to thrombin or 
to the PAR-AP based on the thrombin-revealed PAR-3 tethered ligand sequence, but this  
peptide is able to activate either PAR-1 or PAR-2. Further studies have  
also provided evidence that a possible interaction with PAR-1 and PAR-4 is necessary for 
PAR-3 activation.In addition to the cleavage/activation of PARs, proteinases can also 
negatively regulate PARs function through ‘disarming’ the receptor by cleavage at a site 
downstream the receptor-activating site, to remove the tethered ligand. These truncated 
receptors nonetheless remain responsive to PAR-APs but would be unable to signal in a 
physiological setting. 
In many cases, PARs appear to play a proinflammatory role due to activation of 
proinflammatory mediators and cytokines. In other instances, a protective and anti-
inflammatory role of PARs has been observed53,63-65. 
PAR-1 is the first member of PARs family to be discovered in various cell types 
(endothelium, platelets, and neutrophils). PAR-1 is coupled with different G proteins and can 
activate multiple downstream signalling pathways, including the activation of PI3 kinase, Src 
family tyrosine kinases, the extracellular signal-regulated kinase (ERK)/mitogenactivated 
protein kinase (MAPK) pathway and signalling to nuclear factor (NF)-kB. 
Tumor-expressed PAR-1 play an important role in tumorigenesis of various tissues. Recent 
studies show that in breast cancer cell lines, stromal-derived MMP-1 can activate tumor-
expressed PAR-1 and promote breast cancer cell migration and invasion66,67 (Fig.3).  
In melanoma and colon cancer cell lines that express MMP-1, an inverse MMP-1/PAR-1 
pathway was observed: tumor-derived MMP-1 cleaves microvascular and macrovascular 
endothelial PAR-1, thus generating a prothrombotic and proinflammatory cell surface68. 
Inhibition of this cross-talk may be a powerful means to prevent tumor-induced endotelial cell 
activation and thus thrombotic and inflammatory cell adhesion. 
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Fig.3. MMP-1-mediated PAR1 activation in breast cancer cells leads to increased cell 
invasion. 
 
I.4.3. EF-hand Proteins in Signal Transduction Pathways 
In all eukaryotic cells, Ca2+ ions are important second messengers in a variety of 
cellular signaling pathways and intracellular Ca2+-binding proteins, containing the specific 
Ca2+ binding motif (helix-loop-helix, called EF-hand, Fig.4), are the key molecules to 
transduce signaling via enzymatic reactions or modulation of protein/protein interations upon 
variations in cytosolic Ca2+ concentrations.  
The EF hand proteins, like calmodulin and S100 proteins, are considered to exert Ca2+-
dependent actions in the nucleus, in the cytoplasm and in the extracellular environment. 
 
Fig. 4. Structures of Ca2+-loaded EF-hand motif and EF-hand domain, composed by 
two EF-hand motifs. In red are shown Ca2+ ions bound to the loop of each EF-hand motif. 
 
Calmodulin. Calmodulin (CaM) represents the prototypical intracellular Ca2+-sensor 
containing four Ca2+ binding sites in the loops of four canonical EF-hand motifs69. It is highly 
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conserved and widely distributed in all members of the animal and plant kingdoms, fungi, and 
protozoa, with 100% aminoacid sequence identity among all vertebrates, that synchronize 
cellular responses to cell activation, resulting from an elevation of [Ca2+]70-73. 
In mammals genomes there are three separate genes all coding for a 100% identical CaM 
molecule of 149 aminoacids, including the N-terminal Met.  
CaM is composed of two globular domains, each containing two EF-hand motifs connected 
by a central helix (Fig. 5).  
The pairing of EF-hands enables cooperativity in the binding of Ca2+ ions74. The two domains 
share high overall sequence homology (75%), as well as structural similarity in the presence 
and absence of Ca2+ ions. However, two Ca2+ ions bind with a tenfold lower affinity (Kd ~10-5 
M) to the N-domain than to the C-domain (Kd ~10-6 M). This allows CaM to sense transient 
Ca2+ variations in the cytoplasm over a relatively wide concentration range. Upon Ca2+ 
binding, the linker between the two domains bends round  
        
and CaM assumes a more globular shape, ready to wrap around a substrate recognition site. 
At the same time the two domains undergo conformational changes exposing hydrophobic 
patches that favour target protein interactions75 (Fig. 5). 
CaM can bind to its targets in different ways; in the extended mode interaction its domains 
interact with different regions of the target. The extended binding mode is also used for 
targets that bind to apo-CaM. Many of these targets, such as neuromodulin and neurogranin, 
interact through the IQ motif, which contains the consensus sequence IQxxxRGxxxR76. Some 
IQ motifs bind to CaM in both the absence and presence of Ca2+ (e.g., insulin receptor 
substrate-1, myosin) and in some cases the IQ motif is combined with other CaM binding 
sequences. 
Complexes of CaM with proteins from the family of bHLH transcription factors reveal 
another CaM binding mode that lead to CaM-induced dimerization of the target. 
Fig. 5. Structure of CaM in the apo 
and Ca4 forms. Upon Ca2+ binding, 
the central helix of CaM, 
connecting the N- and C-terminal 
domains, bends round leading to a 
conformational change in the 
overall structure of CaM, and to the 
exposure of hydrophobic residues 
interacting with target proteins. 
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The flexibility of CaM structure and the different binding modes are the key features that 
make CaM able to interact with more than hundred different targets, involved in numerous 
cellular processes such as cell division and differentiation, gene transcription, ion transport by 
channels, membrane fusion and muscle contraction77,77,77-79.  
 
S100 proteins. The S100 proteins are non ubiquitous small acidic proteins (10–12 
kDa) belonging to the EF-hand calcium-binding family, with 25–65% identity at the amino 
acid level and found exclusively in vertebrates, indicating that they are phylogenetically new 
proteins. In human genome, at least 25 members of the S100 proteins are known. Most of 
these genes (S100A1–S100A18, trichohylin, filaggrin and repetin) cluster to chromosome 
1q21, known as the epidermal differentiation complex, which is frequently rearranged in 
human cancer, while other S100 proteins are found at chromosome loci 4p16 (S100P), 5q14 
(S100Z), 21q22 (S100B) and Xp22 (S100G) (Table 1). 
 
Table 1. Nomenclature and chromosomal location of S100 family members. 
 
 
 
The first member was identified in 1965 by Moore from bovine brain, and called  ‘‘S100’’ 
because of its solubility in a 100% saturated solution with ammonium sulphate at neutral pH 
80,81. Since then, the expression of S100 proteins has been demonstrated in a diverse spectrum 
of tissues and involved in the regulation of Ca2+ signal transduction pathways. 
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In vivo and in vitro experiments have shown that the S100 proteins can form non covalent 
homo-and hetero-dimers, with the exception of S100G (Calbindin), which only acts as a Ca2+-
buffering protein. 
The S100 monomer has two distinct EF-hands, one common to all EF-hand proteins on the C-
terminal portion (helixIII-loop-helixIV) and one specific to this family located at the N- 
terminus (helixI-loop-helixII). Downstream the C-terminal EF-hand region is a stretch of 
amino acids referred to as the C-terminal extension. Between the two EF-hand domains is 
the sequence known as the hinge. The C-terminal extension and hinge regions have the most 
variability between the different proteins and hence are responsible for their specific 
biological properties. 
The two EF-hands in each monomer differ in sequence and mechanisms of calcium 
coordination. The 12-residue C-terminal EF-hand binds calcium in a similar manner to 
calmodulin and troponin-C, resulting in a higher calcium affinity site with Kd ~ 10-50 µM.  
 
 
The N-terminal or ‘pseudo-canonical’ EF-hand is formed by 14 residues and binds calcium 
with weaker affinity (Kd ~ 200–500 µM ). The calcium-induced structural changes in the 
S100 proteins are responsible of the exposure of residues from helices III and IV in the C-
terminal EF-hand, and linker region that facilitate the  interaction with target proteins74,75 
(Fig.6). S100A10 is unique within the S100 family, since, upon mutations during evolution, 
both Ca2+-binding sites are inactive and it is locked in the equivalent of a Ca2+-loaded 
structure, thus in a permanently activated state82. Anyway, Ca2+-indepentent functions were 
reported for other S100 proteins. The most common binding partners for the apo-S100 
proteins are enzymes, and also their abilities to form homo- and heterodimers, as well as some 
Fig. 6. Ca2+-binding induces structural 
changes in S100 proteins that allow the 
exposure of key residues involved in target 
proteins interaction. 
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higher-order complexes is an important Ca2+-independent interaction. For example, S100B 
forms the tightest dimer (Kd <500 pM) in the calcium-free state83. 
Interest in the S100 proteins comes from their involvement in several human diseases, such as 
Alzheimer’s disease, cancer and rheumatoid arthritis, usually due to modified levels of 
expression of the S100 members84,85. It is well documented that S100 proteins have a broad 
range of intracellular and extracellular functions (Fig. 7). 
 
 
  
 
Intracellular functions include regulation of different processes: protein phosphorylation 
(MyoD, neuromodulin, tau protein), enzyme activity and metabolism (NDR kinase, guanylate 
cyclase, aldolase C), calcium homeostasis (Annexin A6, AHNAK), cytoskeleton dynamics 
(tubulin, F-actin, intermediate filaments, myosin and tropomyosin), transcription (p53, 
MyoD), metastasis, cell differentiation and shape, proliferation, and membrane trafficking. 
Certain S100 members are released into the extracellular space by an unknown mechanism 
and can regulate cellular activities in an endocrine, paracrine and autocrine manner80, by 
Fig. 7. Schematic representation 
of most of the  intra- and extra-
cellular activities and pathways 
regulated by S100 proteins. 
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interacting with RAGE receptor.The Receptor for Advanced Glycation End products (RAGE) 
has been found to bind some S100 members and transduce signals upon S100 binding86. It is a 
multiligand receptor of the immunoglobulin family, with three domains in the extracellular N-
terminal region, a transmembrane region and a cytosolic domain (Fig. 8). So far S100A4, 
S100B,  S100A12, S100A6, S100A11, S100A13, S100A8/A9, S100P has been identified as 
RAGE ligands. 
S100 proteins use different mechanisms for the interaction with RAGE87. For example, 
S100B in the high Ca2+ extracellular environment is a homotetramer and upon binding to 
RAGE, it mediates receptor dimerization. By contrast, S100A12 is found as a hexamer and 
causes RAGE tetramerization. 
 
 
 
 
 
Recent studies have shown that ligand-activated RAGE can be internalised and targeted to 
vesicles containing endogenous S100B, which are recycled to the plasma membrane and 
secreted by a RAGE-dependent mechanism88.   
Some S100s can interact with receptors different from RAGE (still unknown), with non-
receptor proteins and extracellular matrix components, regulating RAGE-independent 
Fig. 8. Domains organization of RAGE receptor. Extracellular S100 
proteins can bind different domains of the extracellular region of RAGE. 
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activities, moreover the oligomerization state of S100 proteins in the extracellular domain 
showed important functional implications89. 
Extracellular S100s can act as leukocyte chemoattractants, activators for macrophage and 
other inflammatory cells and modulators of cell proliferation. These functions associate S100 
proteins with tissue organization during development and a variety of pathologies such as 
inflammation, cardiomyopathies, and carcinogenesis.  
 
I.4.4.   p53 
The intense interest in p53 has generated up to now more than 47300 publications. 
This interest  on p53 comes from its key role in the maintenance of genomic stability and the 
fact that loss of normal p53 function by mutations occurs in around 50% of human cancers90. 
The p53 is a tumor suppression protein, it induces growth arrest or cell death upon DNA 
damage or other genotoxic stresses and prevents accumulation of mutations in the 
genome91,92. P53 acts mainly as a transcription factor, regulating the transcription of many 
genes involved in cellular processes, including cell cycle, DNA repair, apoptosis, 
angiogenesis, senescence93.  
The major mechanisms involved in modulation of p53 activity  are regulation of p53 protein 
levels, oligomerization, localization and post-translational modifications. P53 structure and 
domain organization reflects its intricate regulatory mechanisms94-96. 
Human p53 is a 393 amino acids protein which consists of four functional domains: the N-
terminal region (1-93), a highly conserved DNA binding domain (residues 94-292), a 
tetramerization domain (residues 325-356) and finally a regulatory C-terminal region of about 
30 residues (Fig. 9). 
The N-terminal region of p53 is natively unfolded and consists of an acidic trans-activation 
domain (TAD) and a proline-rich region97. The TAD is a promiscuous binding site for  
 
Fig .9. Domains organization of p53 monomer. 
Transactivation DNA binding NRD TET 
 NLS  NES 
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different interacting proteins, such as components of the transcription machinery98-100, the 
transcriptional coactivators p300/CBP (CREB-binding protein)101,102, and the negative 
regulators MDM2/MDM4103-105, that play key roles in the regulatin of p53 activity. Moreover 
in the TAD there are sites for posttranslational modifications that further modulate p53 
interactions and activity. For example, in response to stress signals several  protein kinases 
phosphorylate multiple N-terminal serine and threonine residues and in this way can modulate 
the relative affinity for the different proteins that compete for p53 binding106,107. The Proline-
rich domain contains five PXXP motifs, generally mediating numerous protein-protein 
interactions through binding to Src homology 3 (SH3) domains, but the exact role of this 
region is poorly understood. 
The DNA binding domain (DBD) is an immunoglobulin-like β-sandwich, subdivided into two 
structural motifs that bind to the minor groove and major groove of target DNA, 
respectively108. A structural Zinc ion is necessary to maintain thermodynamic stability, DNA 
binding specificity and avoid protein aggregation109,110. 
 P53 bind to specific binding sites in the promoter of its target genes with different affinities, 
depending on the target gene and on posttranslational modification of p53 DBD, such as 
Lysine acetylations111. 
The active form of p53 transcription factor is the tetramer, formed through a tetramerizzation 
domain (TET) in the C-terminal of the protein (Fig. 10). The monomeric TET consists of a 
short β-strand and an α-helix linked by a turn. Two monomers form a dimer, which is 
stabilized via an antiparallel intermolecular β-sheet and antiparallel helix packing with central 
hydrophobic core formed by three key residues (Leu-330, Ile-332, and Phe-341). These 
dimers associate through their helices to form a four-helix bundle tetramer. The tetramer 
interface is stabilized largely by hydrophobic interactions, and the key hydrophobic residues 
are Leu-344 and Leu-348. Dimer are formed cotranslationally on the polysome, whereas 
tetramers posttranslationally, when p53 concentration increases. The Kd for tetramer 
formation is ~ 100 nM. 
In normally proliferating cells p53 is rapidly  degraded by a MDM2-dependent mechanism. 
MDM2 is an ubiquitin ligase, transcriptionally regulated by p53, mediating ubiquitination of 
p53 and targeting to the proteasome. The p53-MDM2 interaction can be impaired by 
phosphorylation of p53 within the MDM2 binding region in response to stress such as DNA 
damage, mediated by the kinases Chk1, Chk2, ATM and ATR that are activated by genotoxic 
damages, leading to increased concentration of p53 in the cells. 
The C-terminal negative regularoty domain (NRD) is intrinsically disordered but can adopt a 
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Fig. 10. (a) Model of p53 in solution from small-angle X-ray scattering data 108. Core and 
tetramerization domains are shown as cartoon representations, flexible connecting linkers 
(gray), N termini (pink), and C termini (yellow) are shown as semitransparent space-filled 
models. (b)  Structure of the tetrameric tetramerization domain (PDB id 1C26), composed by 
a dimer of dimers, stabilized by hydrophobic interactions involving Leu-344 and 348. 
 
helical or a β-turn-like conformation upon binding with regulatory proteins, such as S100 
proteins or CREB-binding protein (CBP), respectively. 
The NRD is also targeted by posttranslational modification, such as acetylation, 
ubiquitination, phosphorylation, sumoylation, methylation, and neddylation, that regulate p53 
tetramerization, localization, DNA binding, and cellular protein levels. 
Since p53 acts mainly as a transcription factor, its localization to the nucleus plays an 
important role and is strictly regulated by interacting proteins, posttranslational modification 
and p53 oligomerization112,113. P53 contains one bipartite basic nuclear localization signal 
(NLS) in the linker region between DBD and TET domains and two nuclear export signals 
(NES), one in the TET domain and one in the N-terminal MDM2 binding region94.  
S100 proteins are important regulators of p53 and act in different way to modulate p53 
tetramerization and function, using different binding sites on p53114.  
Mouse models of human cancers have recently demonstrated that continuous expression of a 
dominantly acting oncogene (H-Ras, K-Ras and Myc) is often required for tumour 
maintenance115,116. Recent studies demonstrated that loss of p53 function may not only play a 
role in the early stages of tumour development, but also be required for the continued 
proliferation and survival of an established tumor. These results put new attention on p53 and 
support efforts to treat human cancers by mechanisms that lead to reactivation of p53. 
 
Leu 348 Leu 348 Leu 344 
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I.5  AIMS AND TOPICS OF THE RESEARCH 
The structural characterization of biomolecular samples, and in particular proteins, 
require high amounts of purified and native samples, and this step is still the major bottleneck. 
During my three years PhD, my work has been focused on the expression and characterization 
of human recombinant proteins, involved in cellular and extracellular pathways. 
The physiological function of a protein is strictly related to its three-dimensional structure 
since in living cells it is regulated by interactions with other proteins and/or macromolecules. 
Different techniques can be used to study protein-protein interactions, and different 
information can be obtained by integrating different approaches. 
Solution NMR spectroscopy is a very useful technique, which can provide information about 
conformational or chemical exchanges, internal mobility and dynamics. In particular, NMR is 
very efficient to map interaction surfaces of  protein/protein  complexes. 
In the first part of my research, NMR spectroscopy has been integrated with Mass 
Spectrometry to study the specificity of proteolytic activity of MMP-1 toward the 
extracellular domain of Protease Activated Receptor-1, which acts as sensor of proteases in 
the extracellular environment of living cells. Proteolytic cleavage of PAR-1 extracellular 
domain can lead to receptor activation, or to an irreversibly disarmed receptor. The effect and 
the signal transduction pathways induced by PAR-1 cleavage depends on the position of the 
cleavage site. Biochemical studies in cultured breast cancer cells, reported PAR-1 as a MMP-
1 target, but the proposed cleavage site does not agree with the known target substrates of 
MMPs in general. The results of the research have provided insight into the physiologic role 
of MMP-1 in PAR-1-mediated signal transduction pathways. 
In another research work, the specificity of the interaction of S100 proteins, and in particular 
S100A2 and S100P, with the tumor suppressor protein p53 has been investigated by NMR 
spectroscopy, native gels and affinity chromatography. This work comes from the observation 
that different S100 proteins interact with p53 and modulate its tumor suppressor activity in 
distinct ways, though S100 proteins share high homology in the sequence and in the structure. 
Since the key role of p53 and S100 proteins in cancer progression, the understanding of their 
interactions at molecular levels can shine light on some mechanisms involved in p53 activity 
modulation. 
The study of protein-protein interactions has been focused also on the interactions between 
Calmodulin and its target proteins. Calmodulin is a key protein for the biology of living cells, 
because it is involved in most signal transduction pathways and is able to interact with a broad 
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range of target proteins. The structural properties responsible for its versatility has not yet 
been fully characterised and the knowledge of its structural properties in complex with target 
proteins and target peptides can lead to some clarifications. Interesting calmodulin targets has 
been selected by bioinformatic and bibliographic research and one of them has been studied in 
complex with Calmodulin by NMR spectroscopy techniques. 
The last project in which I have been involved is focused on the understanding of the 
physiological role of proteolytic activity of MMP-13 in early stages of liver fibrosis. There 
are dissenting opinions on the role of this protease in liver fibrosis. MMP-13 may have 
different roles in the development and in the recovery of liver fibrosis and these roles can be 
associated to its ability to cleave different substrates, which can be differently expressed in 
different stages of the disease. For this purpose, in vivo studies can provide useful information 
on the effect of MMP-13 on the acute liver inflammation that lead to fibrosis and give some 
clues on possible MMP-13 targets.    
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II METHODOLOGIES IN STRUCTURAL BIOLOGY 
 
 
 
 
Structural genomics (SG) programs have been initiated worldwide with the aim of 
solving 3D structure of proteins of living organisms, using high throughput (HT) approaches 
1and leading to an exponential increase of the structures deposited in the PDB.  
Proteins from eukaryotes remain a difficult class of targets for SG studies, especially large 
multidomain or membrane-bound proteins or complexes, but they include important 
biomedical targets, and a large number of them have been subjected to analysis2. Recent 
reports derived from large functional genomics projects seem to indicate that at best only 10-
25% of screened proteins can be adapted to an HT approach and can be used for structural 
characterizations. 
These data highlight the importance of protein expression as a key step for the structural 
biology of interesting proteins not adaptable to HT approaches. For these targets it is 
important to adopt an interdisciplinary approach and exploit any technique that can help in the 
screening of the large number of parameters necessary to identify suitable conditions for good 
samples preparation3. 
Indeed, proteins for structural characterizations are usually required at the milligram level, 
and quantities in the range of 10-50 mg or higher of pure material need to be produced. One 
way to increase the rate of success is to express each target protein in different constructs, 
modified/engineered (for example to eliminate or introduce post-translational modifications, 
or increase solubility, or attach tags, etc), or labelled (deuterated, 15N, 13C, Sel-Met, etc) forms 
to facilitate structural characterizations.  
 II.1. Protein Expression and Purification 
  II.1.1. Construct Design 
 The first and crucial step for the expression and characterization of a recombinant 
protein, is the choice of the construct. In this step, bioinformatic tools are necessary to analise 
the nucleotidic and aminoacidic sequences and obtain informations useful for the choice of 
the constructs. 
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Proteins can have different splicing variants, SNP variants, different isoforms and such 
informations can be acquired by available genomic and proteins sequences databases and 
softwares for predictions. The nucleotidic sequences can be downloaded from databases such 
as GeneBank (http://www.ncbi.nlm.nih.gov/sites/entrez), and Ensembl 
(http://www.ensembl.org/index.html), informations on the aminoacidic sequence, variants, 
isoforms, biophysical properties can be found in Swissprot website 
(http://www.ebi.ac.uk/swissprot/), while informations about predicted or validated SNPs can 
be searched in databases, such as  dbSNPs (http://www.ncbi.nlm.nih.gov/projects/SNP/). 
Information acquired in this first step can help in the choice of the cDNA source, indeed 
many genes are switched off or transcribed at different levels in various cells and tissues and 
in different conditions (health, diseases). 
In order to design different constructs, the target protein properties and domain organization 
must be known or predicted using different tools that have been developed thanks to the huge 
amount of data generated in recent years by different genetic, biochemical and structural 
approaches: 
− Transmembrane region can be predicted   to design constructs and further strategies 
for the expression of a soluble, or transmembrane target or a target  containing both soluble 
and transmembrane domains. (http://www.sbc.su.se/~miklos/DAS/, http://www.cbs.dtu.dk/ 
services/TMHMM-2.0/, http://www.ch.embnet.org/software/TMPRED/form.html);  
− The presence of signal peptide for the protein localization can be predicted  using 
available tools (http://www.cbs.dtu.dk/services/SignalP/)4; 
− Topological and structural predictions can help in the identification of intrinsically 
unstructured regions (http://iupred.enzim.hu/, http://bip.weizmann.ac.il/fldbin/findex/), and 
the prediction of secondary structures (http://npsa-pbil.ibcp.fr/cgibin/npsaautomat.pl?page=/ 
NPSA/npsa_seccons.html) and tertiary structures (http://www.sbg.bio.ic.ac.uk/~3dpssm/); 
− Genome browsing is and approach useful to find proteins sharing the same fold and 
the same consensus sequence within different genomes (www.ncbi.nlm.nih.gov/BLAST), and 
obtain information useful for best predictions; 
− Multiple sequences alignments from different organisms can help in the definition of 
domain borders, since it is known that domains sequences are more conserved during 
evolution than linker regions  (http://align.genome.jp/);  
− Protein domain identification and analysis of protein domain architectures in 
completely sequenced genomes can be performed using SMART tool (http://smart.embl-  
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heidelberg.de/)5; 
− Analyse the protein families structures and domain organization help in the definition 
of a domain (http://www.sanger.ac.uk/Software/Pfam/)  
− Known and predicted protein-protein associations, including direct and indirect 
associations, can be found in the STRING database (http://string.embl.de/); 
− N-terminal sequence should respect the “N-end rule”, that relates the metabolic 
stability of a protein to its N-terminal residue6.  
II.1.2. Cloning strategy 
Recombinant proteins yield and solubility are highly dependent on the specific protein 
sequence, as well as on the vector, host cell, and culture conditions used. The more is known 
about the characteristics of a protein, the more easily it can be expressed, isolated and 
purified. 
For optimal efficiency, various combinations should be simultaneously screened, to determine 
the conditions that yield the ‘best’ sample.  
 The cloning strategy and the expression system are the first steps to be well designed since 
they will influence the expression protocol. The choice of the expression system depend on 
many factors, including cell growth characteristics, expression levels, intracellular and 
extracellular expression, posttranslational modifications, biological activity of the protein of 
interest7,8. 
For example, to express a protein of prokaryotic origin, the obvious choice is to use E. coli as 
host, but in case of eukaryotic proteins, different expression systems can be used and the 
choice will depend on many factors, since each system has its advantages and problems. 
Currently, many methodological improvement in non-prokaryotic hosts made more accessible 
and less expensive eukaryotic systems such as yeast, plants, filamentous fungi, insect or 
mammalian cells grown in culture and transgenic animals9-11. Also cell-free protein syntesis 
has a  great potential for the expression of problematic proteins12, however especially for 
characterizations that require high amount of labelled samples, such as NMR, the prokaryotic 
and in particular the E.coli expression system is the most widely used. The choice of the 
expression vector depends on the expression system. For E. coli, a lot of expression plasmids 
are available for the screening of  different expression conditions that can influence the yield 
of soluble recombinant protein. 
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Plasmid vectors possess an origin of replication (ori), a gene for antibiotic resistance (usually 
AmpR), which allows for selection of cell clones carrying the plasmid, and a multicloning site, 
for the insertion of the target protein coding sequence.  
Classical cloning, using restriction enzymes, typically cannot be adapted to high-throughput 
approaches, due to the complication of selecting compatible and appropriate restriction 
enzymes for each cloning procedure and to its multistep process. High-throughput cloning 
therefore requires procedures which can help the screening of a broad range of conditions in 
less time, for these reasons new cloning technologies have been developed in recent years 
(Fig. 1). 
 
Fig. 1. Schematic representation of  ligase-dependent cloning and TOPO cloning (Invitrogen). 
Classical cloning require multistep procedure, while Gateway technology allow one-step 
cloning in the pENTR vector, and by site-specific recombination ( LR reaction) the target 
gene can be inserted in different expression vectors. 
 
 
Landy and co-workers have found a universal cloning method based on the site-specific 
recombination13. Gateway system (Invitrogen) is based on the bacteriophage lambda site-
specific recombination system which facilitates the integration of lambda into the E. coli 
chromosome and the switch between the lytic and lysogenic pathways. Gateway system uses 
this machinery to clone a target gene into different expression vectors, without the time-
consuming reactions with  restriction enzymes and ligase.  
Important elements of an expression plasmid that affect recombinant protein yield and 
solubility, are: promoter and fusion tag. 
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Many promoter systems are described as tools for protein expression, especially for E. coli 
expression system, but only a few of them are commonly used. A useful promoter must be 
strong, tightly regulated to have a low basal expression level, the induction must be simple 
and cost-effective, and should be independent on the commonly used ingredients of growth 
media. 
The most used promoter system for the bacterial expression of recombinant proteins is the 
T7/lac promoter14. Genes under the control of T7/lac promoter can be transcribed by T7 RNA 
polymerase, in presence of lactose. Prokaryotic cells do not produce this type of RNA 
polymerase, and therefore for the expression of the target proteins can be used only the E. coli 
strains which has been genetically engineered to incorporate the gene for T7 RNA 
polymerase, the lac promoter and the lac operator in their genome. When lactose or a 
molecule similar to lactose, as  Isopropyl β-D-1-thiogalactopyranoside (IPTG), is added to the 
culture, it displaces the repressor from the lac operator. Since there are lac operators upstream 
both the gene encoding the T7 RNA polymerase in the bacterial genome and the target protein 
in the plasmid, IPTG activates both genes. 
T7 RNA polymerase is so selective and active that, when fully induced, almost all of the 
cell’s resources are converted to target gene expression and the desired product can comprise 
up to 50% of the total cell protein in few hours after induction. 
If the basal expression of the recombinant protein must be reduced, as in case of toxic or 
membrane proteins, or for proteins labelling, host strains containing the pLysS or pLysE 
vectors can be used. These vectors express the T7 lysozyme, a natural inhibitor of T7 RNA 
polymerase. 
The target protein can be expressed with different fusion partners, which has been developed 
to increase the expression yield and the solubility of the recombinant proteins, even if 
sometimes the expression of the native protein could be the best choice8.  
 
II.1.3. Protein Expression  
The screening of different conditions for recombinant protein expression require 
handling of a huge amount of samples and an high-throughput approach is very useful1,15,16. 
This approach require first the selection of different representative conditions for a 
preliminary screening, such as fusion tags, promoter systems, E.coli strains, expression 
temperatures, IPTG concentrations. On the basis of these preliminary results, the expression 
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protocol can be optimised and, in case of negative results, it is possible to try the expression 
of mutants, change the cloning strategy, the construct, the expression system. With such an 
approach it is possible to find good expression conditions for may proteins, anyway some 
proteins can be difficult to obtain. 
 The most frequent problems in recombinant protein expression are low expression level, 
degradation, and insoluble protein expression. To date, there is no generally applicable 
strategy to  solve these problems, but there are different way to increase the rate of 
success3,8,17-23. 
Besides using different fusion tags and promoter system, a good analysis of the target gene 
can be useful. Each aminoacid is coded by different codons and the frequency of each codon 
is different in different organisms. For E. coli expression system, rare codons can be predicted  
at http://nihserver.mbi.ucla.edu/RACC/. The frequency of these codons reflects the abundance 
of the tRNAs with the corresponding anticodons, for this reason there are E. coli strains 
engineered to express extra copies of rare tRNAs that can improve the expression of genes 
containing rare codons. 
Another feature that can increase the yield of expressed protein is the sequence immediately 
downstream the start codon that can function as a translational enhancer. Some N-terminal 
tags have been  designed to respect these findings. 
The stability of the recombinant protein with respect to protease degradation can be improved 
targeting the recombinant protein in the periplasmic space or in the growth medium, where 
the concentration of proteases is lower, even if the commercial E. coli strains used for 
recombinant protein expression are engineered to express lower amount of proteases. The co-
expression of the target protein with partner proteins or chaperones can be another way to 
avoid degradation. Also temperature is a key parameter that influence the protein solubility 
and degradation kinetic. Indeed, the expression of target gene under the control of cold-shock 
promoters may have dual effect: decrease the expression of bacterial proteins (and proteases) 
and increase recombinant protein solubility. 
II.1.4. Protein purification 
  The location of expressed protein within the host will affect the choice of methods for 
its isolation and purification. For example, a bacterial host may secrete the protein into the 
growth media, transport it to the periplasmic space, express a cytosolic protein or store it as 
insoluble in inclusion bodies within the cytoplasm. 
 39
For insoluble proteins, the first purification step is the extraction from inclusion bodies. 
Indeed, the most of the bacterial proteins are removed by different extraction steps with native 
buffer conditions, while the recombinant protein is extracted from inclusion bodies with a 
denaturing buffer.  
Physical-chemical properties of the recombinant protein also drive the choice of purification 
protocols, thanks to peculiar properties of the recombinant protein. For instance thermostable 
protein can be purified by thermal shock. Proteins like S100s can be purified by ammonium 
sulfate precipitation or, since they expose hydrophobic residues upon Ca2+ binding, can be 
purified by hydrophobic chromatography and eluted by Ca2+ removal.   
The detection and purification of recombinant proteins can be facilitated by fusion tags that 
can be used for an affinity purification step (Fig. 2), the most used tags are His tag and GST 
tag, purified through IMAC chromatography and immobilised Glutatione columns, 
respectively. 
 
 
Fig. 2. Schematic representation of His tagged recombinant protein purification. After 
expression in host cells, the recombinant protein is extracted from lysed cells. Ni-NTA 
columns can be used ffor purification both in native and denaturing comnditions. 
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After purification, the fusion tag must be removed from the recombinant protein. Indeed, 
expression vectors are engineered to express a protease cleavage site between the fusion tag 
and the recombinant protein. 
When the fusion protein is expressed in inclusion bodies, it must be refolded before 
performing the tag cleavage. Not always this is possible, since fusion tags may interfere with 
protein folding, therefore other methods must be used to obtain the native protein . If the 
protein does not contain other methionines in the sequence, one possibility is the CNBr 
cleavage of starting Methionine. 
Structural information of the target protein, as presence of disulfide bridges, or reduced 
cysteine, or metal binding, can help in the choice of buffer composition, in particular if 
denaturing agents (DTT, β-Mercaptoethanol, Oxidised/Reduced Glutathione,..), chelating 
agents (EDTA,EGTA,..) must be used. 
  
II.2 Biophysical Characterizations 
II.2.1. Light Scattering 
Static and dynamic light scattering represent an approach to studying protein 
complexes and oligomerization. In static light scattering, the scattering intensity is related to 
the molecular weight of the protein, in addition to its concentration, the scattering angle, and 
the wavelength. Dynamic light scattering is based on the auto-correlation of the time-
dependent fluctuations of scattered light intensity, which in turn depends upon the diffusion 
constant. This auto-correlation decays more slowly for slowly diffusing particles and thus, the 
diffusion constant is extracted from the value of the relaxation time of this function. In the 
case of ideal spherical particles, this provides a measure of the molecular weight. Light 
scattering is limited principally by sensitivity, with best results around 1 mg/ml, depending 
upon the size of the protein or the complex. While sensitivity limits preclude the 
determination of affinities and association or dissociation rate constants in most cases, light 
scattering is quite useful in characterizing the stoichiometry of complexes at high 
concentration. This is very important information for the analysis of data obtained by more 
sensitive techniques. In fact, it should be pointed out that in many cases, biochemical methods 
provide the information that protein A interacts with protein B, but the stoichiometry of this 
interaction is often elusive. Even when crystal structures are available, the stoichiometry of 
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the complex in the crystal may not correspond to that observed in solution under various 
conditions.  
 
II.2.2. Mass Spectrometry 
Mass spectrometry is an analytical tool used for measuring the molecular mass of a 
sample. 
For large samples such as biomolecules, molecular masses can be measured to within an 
accuracy of 0.01% of the total molecular mass of the sample. Mass Spectrometry can be used 
for different types of characterization: 
− Accurate molecular weight measurements, to determine the purity of a sample, to 
verify amino acid substitutions, to detect post-translational modifications, to calculate the 
number of disulphide bridges;  
− Reaction monitoring: monitor enzyme reactions, chemical modification, protein 
digestion;  
− Amino acid sequencing: sequence confirmation, characterisation of peptides, 
identification of proteins by database from proteolytic fragmentation;  
− Protein structure: protein folding monitored by H/D exchange, protein-ligand complex 
formation under physiological conditions, macromolecular structure determination. 
Mass spectrometers can be divided into three fundamental parts: the ionisation source , the 
analyser and the detector. 
Sample molecules are ionised in the ionisation source, these ions are extracted into the 
analyser region of the mass spectrometer where they are separated according to their mass (m) 
-to-charge (z) ratios (m/z) . The separated ions are detected and this signal sent to a data 
system where the m/z ratios are stored together with their relative abundance for presentation 
in the format of a m/z spectrum. 
Many ionisation methods are available, each with its own advantages and disadvantages, and 
the choice depend on the type of sample under investigation and the mass spectrometer 
available.  
The ionisation methods used for the majority of biochemical analyses are Electrospray 
Ionisation (ESI) and Matrix Assisted Laser Desorption Ionisation (MALDI). 
The main function of the mass analyser is to separate , or resolve , the ions formed in the 
ionisation source of the mass spectrometer according to their mass-to-charge (m/z) ratios. 
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There are a number of mass analysers currently available, the better known of which include 
quadrupoles , time-of-flight (TOF) analysers, magnetic sectors , and both Fourier transform 
and quadrupole ion traps . 
These mass analysers have different features, including the m/z range that can be covered, the 
mass accuracy, and the achievable resolution. 
The detector monitors the ion current, amplifies it and the signal is then transmitted to the 
data system where it is recorded as mass spectra, where the m/z values of the ions are plotted 
against their intensities to show the number of components in the sample, the molecular mass 
of each component, and the relative abundance of the various components in the sample. 
MALDI is widely used in biochemical areas for the analysis of proteins, peptides, 
glycoproteins, oligosaccharides, and oligonucleotides and usually is performed in denaturing 
conditions. 
MALDI is based on the bombardment of sample molecules with a laser light to bring about 
sample ionisation. The sample is pre-mixed with a highly absorbing matrix compound which 
transforms the laser energy into excitation energy for the sample, which leads to sputtering of 
analyte and matrix ions from the surface of the mixture.  
The time-of-flight (TOF) analyser separates ions according to their mass(m)-to-charge(z) 
(m/z) ratios, by measuring the time it takes for ions to travel through a field free region known 
as the flight tube. The heavier ions are slower than the lighter ones. 
In negative ionisation mode, the deprotonated molecular ions (M-H-) are usually the most 
abundant species, accompanied by some salt adducts and possibly traces of dimeric or doubly 
charged materials. Negative ionisation can be used for the analysis of oligonucleotides and 
oligosaccharides. In positive ionisation mode, the protonated molecular ions (M+H+) are 
usually the dominant species, although they can be accompanied by salt adducts, a trace of the 
doubly charged molecular ion at approximately half the m/z value, and/or a trace of a dimeric 
species at approximately twice the m/z value. Positive ionisation is used in general for protein 
and peptide analyses. 
II.2.3. Native gel Electrophoresis 
An important tool for the biochemist is the ability to analyze proteins in their native 
state. Many electrophoresis of proteins and protein:protein complexes in native 
polyacrylamide gels have been described24. This method allows to separate native proteins 
according to differences in their charge density but not according to molecular weight. 
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Native gel electrophoresis does not use charged denaturing agents, for this reason some 
proteins may faile to run in acrylamide native gel electrophoresis. 
An alternative technique is the native agarose gel25, that has the additional advantage of 
allowing the detection of both positively and negatively charged proteins which migrate 
toward the anode and cathode, respectively, as well as protein: protein complexes in the same 
gel. To be sure of the complex formation, the corresponding band can be cut from the gel and 
the components separated in SDS-PAGE to verify the presence of the two proteins in the 
complex. 
 
II.2.4. Spectrophotometric Activity assay 
Recombinant enzymes, especially those which undergo refolding steps during 
preparation, have to be checked for activity. Spectrophotometric assays are widely used for 
determination of enzymatic activity and rely on the difference in molar absorptivity between 
substrates and products. Since in the UV range  the absorbance of proteins may interfere with 
the measurements, the visible range is preferred for these determinations. Substrates used for 
these assays are constructed from natural substrates, with new substituents added in order to 
impart a chromogenic property to the substrate upon the enzymatic reaction, which allows 
simple quantification. 
One example of chromogenic substrate is a commercial chromogenic substrate for 
spectrophotometric assay of most matrix metalloproteinases. The MMP cleavage site peptide 
bond is replaced by a thioester bond in this peptide. Hydrolysis of this bond by an MMP 
produces a sulfhydryl group, which reacts with DTNB [5,5'-dithiobis(2-nitrobenzoic acid), 
Ellman's Reagent] to form 2-nitro-5-thiobenzoic acid, which can be detected by its 
absorbance at 412 nm. 
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II.3. Structural Characterizations 
Nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography can 
provide high-resolution structures of biological molecules such as proteins and nucleic acids 
and their complexes at atomic resolution. NMR can study molecules in solution, therefore, 
crystallization is not required, and crystal packing affects may not influence the structure, 
especially on the surface of a protein. Solution studies should be closer to native-like 
conditions found in the cell. Since crystals are not needed, protein folding studies can be 
monitored by NMR spectroscopy upon folding or denaturing of a protein in real time. More 
importantly, denatured states of a biomolecule, folding intermediates and even transition 
states can be characterized using NMR methods. NMR provides information about 
conformational or chemical exchanges, internal mobility and dynamics at timescales ranging 
from picoseconds to seconds, and is very efficient in determining ligand binding, and 
mapping interaction surfaces of  protein/protein, protein/nucleic acid, protein/ligand or 
nucleic acid/ligand complexes and intramolecular interactions. Improvements in NMR 
hardware (magnetic field strength, cryoprobes) and NMR methodology, combined with the 
availability of molecular biology and biochemical methods for preparation and isotope 
labeling of recombinant proteins, have dramatically increased the use of NMR for the 
characterization of structure and dynamics of biological molecules in solution. Protein isotope 
labelling is necessary for NMR analysis because not all atoms are magnetically active. 
The nuclei of naturally occurring atomic isotopes that constitute biological molecules have a 
nuclear spin determined by the spin quantum number (I) and its value depends on the 
composition of neutrons and protons in each nucleus. Because of the positive charge 
possessed, the nucleus rotation around its own axis generate a magnetic moment (m). Only 
atoms with I≠0 can be observed by NMR spectroscopy. For example, 12C is the most 
abundant isotopes in nature,  but it has I=0, for this reason labelling with 13C is performed for 
biomolecules studied by NMR spectroscopy. 
Nuclei which have a spin of one-half, like 1H, or 13C, have two possible spin states: m = ½ or 
m = -½ (also referred to as α and β, respectively). The energies of these states are degenerated, 
hence the populations of the two states will be approximately equal at equilibrium. 
If a nucleus is placed in a magnetic field, there is interaction between the nuclear magnetic 
moment and the external magnetic field, then the nuclear spin state aligned with the external 
magnetic field will be more populated and the different states will have different energies. 
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When a radiofrequency pulse is applied to match this energy difference, resonance absorption 
will occur and all nuclei of the same element would resonate at the same frequency. The 
resonance frequency is affected by the chemical environment of each nucleus, hence nuclei of 
the same element will have differences in the resonance frequency due to the interference of 
surrounding electrons, that decrease the magnitude of the effective magnetic field on the 
nucleus. These differences are called chemical shifts and are higher for more shielded nuclei. 
The chemical shift value depends also on the applied magnetic field and in order to have 
chemical shift values normalised on the static magnetic field strength, they are measured in 
parts per million (ppm). 
In a protein, the resonance frequencies of each nucleus vary slightly due to chemical shifts, 
then a very short radiofrequency pulse is applied which inherently encodes a range of 
frequencies allowing to induce resonance for the whole frequency spectrum in one experiment 
(Fourier transform, FT NMR). Transient signals are detected as the system returns to 
equilibrium. The response obtained from a FT NMR experiment is a superposition of the 
frequencies of all spins in the molecule as a function of time. In order to obtain the 
corresponding spectrum as a function of frequency, a Fourier transformation is performed. 
Fourier transformation is a mathematical operation which translates a function in the time 
domain into the frequency domain. 
Ideally, each distinct nucleus in the molecule experiences a distinct chemical environment and 
thus has a distinct chemical shift by which it can be recognized. However, in large molecules, 
such as proteins, the number of resonances can be several thousand and a one-dimensional 
spectrum inevitably has overlaps. For this reason, proteins NMR spectra cannot be resolved in 
a conventional one-dimensional spectra (1D) and multi-dimensional nuclear magnetic 
resonance spectroscopy is required to correlate the frequencies of different nuclei. There are 
different types of experiments that can detect through-bonds and through-space nucleus-
nucleus interactions. 
The  Heteronuclear Single Quantum Correlation (HSQC) spectrum is a 2D spectrum, where 
"heteronuclear" refers to nuclei other than 1H. In theory the heteronuclear single quantum 
correlation has one peak for each H bound to a heteronucleus. Thus the 1H 15N-HSQC 
spectrum contains the signals of the HN protons in the protein backbone. Since there is only 
one backbone HN per amino acid, each HSQC signal represents one single amino acid, with 
the exception of proline, which has no amide-hydrogen due to the cyclic nature of its 
backbone. Moreover, this HSQC also contains signals from the NH2 groups of the side chains 
of Asn and Gln and of the aromatic HN protons of Trp and His.  
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The acquisition of NMR signals is performed during the relaxation process, which restore the 
equilibrium of the system. There are two types of relaxation: 
− transverse relaxation, due to the interaction between different spins, and measured by 
the T2 time, which is directly proportional to the molecular weight; 
− longitudinal relaxation, due to the interaction between spins and solvent molecules, 
and is measured by the T1 time. 
The main problem in studies of biomolecules with molecular weights above 30 kDa is the fast 
decay of the NMR signal due to relaxation. Indeed, the line widths in the NMR spectra are 
inverse proportional to the relaxation rates. Therefore the signal-to-noise in NMR spectra of 
larger molecules is poor, due to poor resolution and sensitivity. There are NMR methods  that 
can help the acquisition of spectra of large biomolecules, one of them is Transverse 
Relaxation Optimized Spectroscopy (TROSY). With these improvements high-resolution 
TROSY-HSQC spectra can be recorded of macromolecules with MWs up to several 100 000 
Daltons.  
The exchange between two conformations, e.g. free and ligand bound forms of a protein, but 
also chemical exchange usually gives rise to two distinct NMR signals for a given spin due to 
different chemical environments in the two exchanging forms. If the exchange rate is slow on 
the chemical shift time scale, two sets of signals are observed, if the exchange rate is fast on 
the chemical shift time scale only one signal is observed at an average frequency 
corresponding to the populations of the two conformations. Intermediate exchange gives rise 
to very large line width.  
Molecular interactions can be very efficiently characterized using very sensitive NMR 
experiments. Changes in the environment of a spin due to binding of a ligand give rise to 
chemical shift changes in the NMR spectrum. These changes are usually largest near the 
binding site. Therefore, the binding surface of a protein with a ligand can be mapped. In 
addition, from NMR titration experiments dissociation constants can be determined. Due to 
the relatively high sample concentration, even very weak interactions can be detected. 
Additional structural information, and long range interactions, as the relative orientation of 
two protein domains can be measured by the observation of Residual Dipolar Couplings 
(RDCs). 
Dipolar coupled spins are the result of spin/spin interactions through space and depend on the 
distance between the two spins and the orientation of the internuclear vector with respect to 
the static magnetic field B0. The chemical shift difference between 1H-15N (1H-15N J-coupling 
constant), is different in isotropic or anisotropic conditions. There are different method for 
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aligning molecules in solution: prepare NMR samples in slightly anisotropic solutions or 
replace the native metal ions in a molecule with paramagnetic ones, which are able to align 
the molecules in a magnetic field. In order to measure RDCs, signals of 15N-HSQC 
experiments must be splitted, and this implies that the numbers of signals doubles with 
respect to normal HSQC, hence, for proteins this will result in a crowded spectrum. To avoid 
this problem, two coupled spectra can be acquired, one will contain the component of the 
coupled magnetization inphase with the external magnetic field and the other the antiphase 
component. The IPAP (In-Phase AntiPhase) strategy, adopt this technique, moreover it 
partially overcome the problem of loss of peaks intensity. 
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The signal transduction pathways that are induced by the acti-
vation of G protein-coupled proteinase-activated receptors
(PARs) play a role in several physiological and pathological pro-
cesses such as hemostasis, inflammation, angiogenesis, cell
ACHTUNGTRENNUNGadhesion, cancer invasion and metastasis.[1] The molecular
basis of PAR-1 triggering has been extensively investigated. In
particular, the mechanism by which thrombin, the natural acti-
vator of PAR-1, cleaves the protein at the R41–S42 site and un-
masks the N-terminal peptide S42FLLRN47 has been clarified by
NMR spectroscopy, mass spectrometry and molecular biology
experiments.[2] Recently, it has been proposed that PAR-1 can
also be activated at the same cleavage site by matrix metallo-
proteinase-1 (MMP-1)[3] and that this non-physiological process
can promote invasion and metastasis in several tumor lines
where MMP-1 is found to be overexpressed by stromal cells.[4]
However, in our and many other researchers’ experience
with the recognition of target substrates by MMPs,[5] cleavage
at an Arg-Ser peptide bond is unexpected. Even though the
broad substrate specificity of MMPs makes it difficult to safely
predict the cleavage sites, an amino acid residue with a lipo-
philic side chain that is downstream of this cleavage site usual-
ly fits much better into the S1’ pocket of the enzyme, and a
Ser residue is quite unfit for this interaction. In this work, we
sought to prove—or disprove—the cleavage of PAR-1 at the
R41–S42 bond by MMP-1. These findings might open up new
prospects in the understanding of the biology and pharmacol-
ogy of this class of receptors.
The PAR-1 exodomain A26–L103 is recognized and activated
by its physiological partner thrombin.[2] The construct A26–
L103 is therefore a biologically meaningful model to study this
interaction with MMP-1, and to verify new hypotheses on the
activation mechanism. The degradation of the N-terminal
domain of PAR-1 by thrombin, which occurs at submillimolar
concentrations, has been already monitored by NMR spectros-
copy,[2] and was thus used as a reference in the present work.
An analysis of the thrombin- and MMP-1-mediated proteoly-
sis of PAR-1 was carried out in parallel by using 40 mm samples
of the construct A26–L103 in a buffer that contained 10 mm
Tris (pH 7.2), 5 mm CaCl2, 0.1 mm ZnCl2 and 0.3m NaCl (Fig-
ACHTUNGTRENNUNGures S1 and S2 in the Supporting Information). The NMR spec-
tra that were acquired to monitor the thrombin–PAR-1 interac-
tion nicely reproduced the already published data, where the
proteolysis at the scissile bond R41–S42 and the structure of
the cleaved peptides were well characterized (Figure 1A). On
the contrary, the 1H,15N HSQC spectra of the 15N-enriched PAR-
1 exodomain (collected at different times) after the addition of
recombinant MMP-1, showed a completely different pattern of
signal changes (Figure 1B). In addition, the proteolysis that is
catalyzed by MMP-1 is much slower than that of thrombin,
where a few minutes in presence of 0.2 mm of enzyme at 278 K
were enough to process all of the PAR-1 polypeptide that was
present in solution. The PAR-1 proteolysis by MMP-1 was moni-
tored at 298 K for 53 h (Figure S2). The higher enzyme concen-
tration (up to 3 mm) and the higher temperature were needed
to accelerate the proteolytic cleavage of PAR-1 to a suitable
extent.
The profile of the enzymatic digestion was determined by
matrix-assisted laser desorption/ionization (MALDI) mass spec-
trometry (MS) on aliquots of the original 15N-labelled samples
with a degree of enrichment of 97.1%. The analysis of the
PAR-1 exodomain A26–L103 and of the resultant proteolytic
products, which was performed by MS confirmed important
differences between the proteolytic cleavage of PAR-1 by
thrombin and by MMP-1. Most of the peptides that were de-
[a] Dr. A. Nesi, Dr. M. Fragai
Magnetic Resonance Center, University of Florence
Via L. Sacconi 6, 50019 Sesto Fiorentino, Florence (Italy)
Fax: (+39)0554574253
E-mail : fragai@cerm.unifi.it
[b] Dr. M. Fragai
Department of Agricultural Biotechnology, University of Florence
Via Maragliano 75–77, 50144 Florence (Italy)
Supporting information for this article is available on the WWW under
http://www.chembiochem.org or from the author.
Figure 1. A) 1H,15N HSQC spectra at 278 K of the native A26–L103 PAR-1 exo-
domain (40 mm) ; the resonances that are affected by the proteolytic activity
of thrombin are in red. B) 1H,15N HSQC spectra at 278 K of the native A26–
L103 PAR-1 exodomain (40 mm) ; the resonances that are affected by the
faster full-length active MMP-1 hydrolysis are in red, and the resonances
that are affected by the slower hydrolysis are in cyan.
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tected in the spectra appeared
as single-charged monoproto-
nated molecular ions at m/z
[M+H]+ . The fragment analysis
is reported in Table 1. The prog-
ress of PAR-1 digestion by
thrombin was followed by peri-
odically removing aliquots after
the addition of the enzyme. An
incubation time of a few mi-
nutes with 0.2 mm of thrombin
was enough to completely
cleave the native polypeptide at
a single cleavage site between
R41 and S42 (Scheme 1). After 5 min, the peak of the original
peptide A26–L103 disappeared, and only two peaks of m/z
1810 and m/z 7263, which correspond to the N-terminal A26–
R41 and the C-terminal S42–L103 fragment, respectively, re-
mained in the spectra. These two fragments were not further
degraded, even after long incubation times. The fast enzymatic
degradation of PAR-1 by thrombin under these experimental
conditions nicely match with the reported data.[2,7] As was also
demonstrated by NMR spectroscopy, the hydrolytic activity of
MMP-1 toward PAR-1 was much slower than that of throm-
bin.
For the MMP-1-treated samples, a mass peak of m/z 7311,
which is related to a cleavage between F87 and I88 and two
other peaks of m/z 2159 and m/z 6912, which correspond to
the N-terminal A26–L44 and to the C-terminal L45–L103 frag-
ment, respectively, were detected in the spectra after an incu-
bation time of 15 min at 278 K. The existence of these two in-
dependent cleavage sites was also confirmed by the presence
of mass peaks that correspond to degradation products from
the already-formed fragments L45–L103 and A26-F87, as well
as the peptide A26–R70, which was present as a contaminant
also in the absence of the enzyme. Even after long incubation
times, peaks that corresponded to the thrombin cleavage sites
could not be found in the spectra. The same results were
ACHTUNGTRENNUNGobtained by using the catalytic domain of MMP-1 instead of
the full-length active protein. From a careful analysis of the
1H,15N HSQC, two kinetically distinct hydrolytic processes could
be detected; a first set of signals disappeared faster and a
second set more slowly, this was accompanied by the reap-
pearance of new signals, which also had different time courses.
The intensity changes of selected signals that belong to the
two sets are shown in Figure 2.
Stepwise proteolysis at the peptide bonds F87–I88 and L44–
L45 is consistent with the 1H,15N HSQC spectra, according to
the reported assignment. A correlation of the cleavage sites
with the two kinetically distinct processes could also be estab-
lished, because the faster hydrolysis affected the resonances
that correspond to F87 and I88, while the loss of the L45
signal was associated with the slower one. The other degrada-
tion products that were identified by MS could not be detect-
ed by NMR due to their low concentration, even up to 53 h
after the addition of the enzyme. The analysis of the intensity
profiles, which was performed on isolated NMR signals provid-
ed half-lives of 4.9 h and 8.6 h for the two processes, respec-
Table 1. MALDI/MS analysis of PAR-1 exodomain and of its cleavage products after digestion with thrombin and MMP-1 respectively.
PAR-1 ACHTUNGTRENNUNG(A26–L103) PAR-1ACHTUNGTRENNUNG(A26–L103)+ thrombin PAR-1 ACHTUNGTRENNUNG(A26–L103)+MMP-1
ACHTUNGTRENNUNG[MH]+ Fragment analysis ACHTUNGTRENNUNG[MH]+ Fragment analysis ACHTUNGTRENNUNG[MH]+ Fragment analysis
9053.84 A26–L103 8948.9+ (107-N) 97.1% 9053.84 A26–L103 8948.9+ (107-N) 97.1% 9053.84 A26–L103 8948.9+ (107-N) 97.1%
5438.32 A26–R70 5371.8+ (68-N) 7262.98 S42–L103 7183.9+ (80-N) 7311.27 A26–F87 7224+ (90-N)
3631.95 L71–L103 3595.1+ (39-N) 1809.85 A26–R41 1782.9+ (27-N) 6911.70 F45–L103 6836.5+ (77-N)
5437.38 A26–R70 5371.8+ (68-N) 5168.02 L45–F87 5111.6+ (60-N)
3631.90 L71–L103 3595.1+ (39-N) 2159.03 A26–L44 2130.3+ (30-N)
5436.56 A26–R70 5371.8+ (68-N)
3631.97 L71–L103 3595.1+ (39-N)
3295.49 F45–R70 3259.4+ (38-N)
1891.90 L71–F87 1870.2+ (22-N)
Scheme 1. Cleavage sites of thrombin and of MMP-1 on the A26–L103 PAR-1 exodomain. The reported functional
hexapeptide SFLLRN is highlighted in red.
Figure 2. Normalized intensity profiles of 2D 1H,15N HSQC signals for I88 (!),
L45 (N) and for two new signals of the proteolytic fragments (*, &). Two
ACHTUNGTRENNUNGkinetically distinct hydrolytic processes are detected.
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tively (Figure S3). Past experience with MMPs also suggests
that the cleavage at the F87–I88 and L44–L45 sites is much
more plausible, because it is widely reported that a hydropho-
bic amino acid (L45 or I88 in this case) is usually present at the
P1’ position to interact with the S1’ binding site of the MMP-1
enzyme.[4] This specificity is also in agreement with the “snap-
shots” that were recently obtained along the catalytic mecha-
nism of matrix metalloproteinases.[6]
The observation of a different specificity between thrombin
and MMP-1 for PAR-1 raises several questions about the mech-
anism by which MMP-1 activates the receptor. As previously
ACHTUNGTRENNUNGreported for other proteases, proteolysis downstream of what
is widely believed to be the functional SFLLRN hexapeptide,
which is the tethered ligand of the PAR-1 exodomain would be
expected to permanently inactivate the receptor.[7] Conse-
quently, the cleavage at the F87–I88 position should be fol-
lowed by PAR-1 desensitization. The biological data on the ca-
pability of MMP-1 to activate the receptor[3] suggest that this
cleavage site, which is near the cellular membrane, might not
be easily accessible in vivo for the enzymatic hydrolysis by
MMP-1.
The cleavage that occurs at L44–L45, right in the middle of
the SFLLRN hexapeptide is much more interesting. The loss of
the first three amino acids would be expected to strongly de-
crease or even to abolish the biological activity because sever-
al structure–activity studies that were performed by using li-
braries of peptides and receptor mutants have established that
the amino acids at position 2, 4, and 5 of the hexapeptide are
most important for PAR-1 activation.[1,8] Apparently, this is not
the case.
An interesting observation is that the biological activity of
synthetic hexapeptide analogues, though decreased, is still
present in shorter fragments.[8] This weak activity is probably
related to a reduced affinity for the receptor that is caused by
the loss of intermolecular interactions from the missing amino
acids. Unlike the free peptides that were used in structure–
activity studies, in the proteolytic unmasking of the N-terminal
SFLLRN ligand, the tethering contribution to the binding that
is due to the link between the residual PAR-1 exodomain and
the receptor has to be taken into account. This phenomenon,
which has been widely exploited in drug discovery to increase
the affinity of weak ligands,[9] could explain an at least partial
PAR-1 activation by the MMP-1-mediated cleavage at the L44–
L45 site.
Although the low efficiency in PAR-1 proteolysis with respect
to thrombin could call into question the role of MMP-1 in the
invasiveness of breast cancer cells, the involvement of intersti-
tial collagenase in this pathological process has been demon-
strated.[3] Currently, the reported bimodal activity of thrombin
on tumor cell migration (promoting at low, inhibiting at high
concentration)[3] suggests that the low cleavage efficiency of
MMP-1 might be pathologically relevant.
Experimental Section
Expression and purification protocols of PAR-1 (A26–L103), of the
full-length active human fibroblast collagenase G99–N463, and of
its catalytic domain N106–G261 are described in detail in the Sup-
porting Information. The enzymatic activity of MMP-1 (400 Umg1)
was determined by using a colorimetric assay (Biomol cat. P-125).
Human thrombin was purchased from Sigma–Aldrich. Protein con-
centrations were determined by a Bradford Assay (Pierce). For all
NMR and MS experiments, the PAR-1 exodomain (A26–L103) was
resuspended in Tris (10 mm, pH 7.2), NaCl (0.3m), CaCl2 (5 mm),
ZnCl2 (0.1 mm) at a final concentration of 40 mm. A PAR-1 concen-
tration of 40 mm was used in order to ensure the stability of the
samples for the extended times that were required to monitor the
proteolytic activity of the enzymes, and to avoid the precipitation
that easily occurs at higher concentrations.
The mass spectrometry investigation was performed by incubating
40 mm PAR-1 (A26–L103) solutions with thrombin (0.2 mm) and with
either full-length active MMP-1 (0.5 mm) or its catalytic domain at
278 K in a buffer that contained Tris (10 mm pH 7.2), CaCl2 (5 mm),
ZnCl2 (0.1 mm) and NaCl (0.3m). Samples at different reaction times
were collected and the reaction was stopped by acidification with
0.25% TFA. The reaction samples were purified by Zip Tip (Eppen-
dorf) and analyzed on a Bruker Ultraflex TOF/TOF.
The NMR analysis of the thrombin-mediated proteolysis was car-
ried out by recording the 1H,15N HSQC spectra at 278 K. The pro-
teolytic activity of MMP-1 was investigated by adding increasing
concentrations of the enzyme (up to 3 mm) to a PAR-1 sample and
by monitoring the reaction at 298 K.
All the spectra were acquired on a Bruker DRX 800 MHz spectrom-
eter, equipped with a TXI cryo-probe.
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Protein Expression and Purification: The N-terminal extracellular domain fragment 
of PAR-1 (A26-L103) was amplified by PCR from the full-length active cDNA clone 
(RZPD) by using primers required by Gateway TOPO Cloning Reaction (Gateway 
Cloning Technology, Invitrogen): Forward: CACC ATG GGG CCG CGG CGG CTG 
CTG  - Reverse: CTA GAG TGT CAG CCA GGA GCT. The purified PCR product 
was cloned into the pENTR/TEV/D-TOPO vector to obtain the pENTR clone and se-
quenced. Then the PAR-1 construct was inserted into the pDEST 17A vector by an 
LR clonase reaction to create the expression vector containing the His tag – TEV 
cleavage site – PAR-1(A26-L103) construct. The recombinant PAR-1 protein was 
expressed in E. coli strain Gold . The cells were grown at 37°C until OD600 of 0.8 was 
reached. The protein expression was induced by addition of 1 mM IPTG. The cells 
were allowed to growth further at 30°C for 18-20 h and then harvested by centrifuga-
tion. The inclusion bodies, containing the recombinant protein, were solubilized in 
20 mM Tris, 0.5 M NaCl, 8 M Urea, 5 mM imidazole (pH 7.5) and purified with Ni2+-
loaded HiTrap Chelating  column (Amersham). A yield of 50 mg of 15N labelled puri-
fied protein per liter of culture was obtained. The recombinant protein was cleaved at 
starting methionine to remove the N-terminal tag using CNBr/70% Formic Acid, puri-
fied by RP-HPLC as described,[1] lyophilised and stored at –80°C.  
 2 
The full-length active human fibroblast collagenase G99-N463 and the catalytic do-
main N106-G261 were expressed in E. coli. The cDNA was cloned into the pET21 
vector (Novagen) using Nde I and Xho I as restriction enzymes. The E. coli strain 
BL21 Gold cells, transfected with the above vector, were grown in 2 ´ YT media at 
37°C. The protein expression was induced during the exponential growth phase with 
0.5 mM of IPTG. Cells were harvested for 4 h after induction. The cells were lysed by 
sonication and the inclusion bodies, containing the MMP-1, were solubilized in 6 M 
guanidine hydrochloride and 10 mM DTT. Then the solution was diluted, without puri-
fication, in a buffer containing 50 mM Tris (pH 7.2), 10 mM CaCl2, 0.1 mM ZnCl2, 0.3 M 
NaCl, 2.3 M guanidine hydrochloride, 20% glycerol, 2.5 mM GSSG, and 2.5 mM GSH 
at pH 7.8. The refolded protein was exchanged, by dialysis, against a buffer with 
50 mM Tris (pH 7.2), 10 mM CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl. The protein was puri-
fied on the Hitrap Q column (Pharmacia). 
________________________ 
[1] A. Kuliopulos, C. T. Walsh, J.Am.Chem.Soc. 1994, 116, 4599-4600. 
 
 
 
Figure S1. 1H-15N HSQC spectra at 278 K of the native A26-L103 PAR-1 exodomain (40 mM) 
before (A) and 24 hours after the addition of thrombin 0.2 mM (B). 
 3 
 
 
 
Figure S2. 1H-15N HSQC spectra at 298 K of the native A26-L103 PAR-1 exodomain (40 mM) 
before (A), 7.5 h after (B) and 53 h after (C) the addition of active full length MMP-1 (3 mM). 
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Figure S3. Normalized intensity profiles of the 2D 1H,15N HSQC signals related to the two 
kinetically distinct hydrolytic processes  with half-lives of 4.9 h (7) and 8.6 h (,) respectively. 
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IV. Proteolytic anti-inflammatory activity of  catalytic domain of human 
MMP-13 on murine models of liver fibrosis 
 
 
 
 
 
 
Abstract 
AIM: On the basis of the already known double roles of MMP13 in the promotion of early stages 
of inflammation induced by liver injury and in the fibrosis resolution in rodent models of liver 
fibrosis, the effects of treatment of murine models of CCl4-induced liver fibrosis with catalytic 
domain of recombinant human MMP13  were evaluated. METHODS: Mice and rats were 
randomly divided in four groups: control, treated with CCl4, treated with MMP13, and treated 
with both CCl4 and MMP13. Liver tissue sections from each group were stained with H&E for 
morphological examination and with Sirius Red for collagen visualization. RESULTS: The non-
collagenolytic proteolytic activity of cat-MMP13 plays a key role in the reduction of the 
inflammatory process induced by CCl4 treatment, by reducing the amount of necrotic cells and 
inflammatory cells in the hepatic tissue.  
 
 
Key words: Liver fibrosis – CCl4 – MMP13 – Inflammation – Necrosis. 
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Introduction 
During liver fibrosis there is a pathologic imbalance between the formation and the degradation 
of extracellular matrix. The main actors of this remodeling are the stellate cells (HSC) that 
produce collagen and matrix metalloproteinases (MMPs), that specifically degrade extracellular 
matrix proteins 1-4 
A number of studies have provided evidence of their involvement in remodeling during fibrotic 
and/or inflammatory processes in the liver and in other organs. MMPs are involved in various 
processes, including ovulation, embryogenic growth and differentiation, tumor invasion and 
metastasis 5-8. The activity of MMPs may be regulated at the level of gene transcription, during 
proenzyme activation, and by binding of the proenzyme or active enzyme to specific inhibitors 
(TIMPs). More than 23 MMPs7 and 4 TIMPs have been identified so far, and, among them, 
MMP-1,-2,-3,-7,-8,-9,-10,-13,-14,-15 and -16 are expressed in the liver, especially in stellate cells 
which are well known as main cell source of extracellular matrix, MMPs and TIMPs 9-11. The 
intraperitoneal administration of the hepatotoxic CCl4 to mice, is a well established model to 
investigate liver fibrosis12. Usually, after a single injection of CCl4, a strong inflammation left the 
place to liver fibrosis that spontaneously reverts in few days. Upon  liver injury, a specific 
chronological succession chronological succession of events is activated13,14. In detail, twelve 
hours after the intraperitoneal injection of CCl4 in mice, hepatocyte ballooning began around the 
central vein, and hepatic necrosis occurrs adjacent to the central vein. Zonal necrosis with 
infiltrating cells, such as macrophages and lymphocytes, is observed at 48-72 hours around the 
central vein. The necrotic change is diminished at 5 days with a complete regression to normal 
liver at 7 days. Reticular fibers are increased around the necrotic areas at 5 days and decreased 
again at 7 days. This modulation in the ECM is linked to relative increased expression of the 
MMPs: at 6 hours after the intoxication, the expression of MMP-13 (collagenase 3), which is 
seldom detected in normal liver, is clearly increased until 12 hours and then decreased again at 24 
hours. Others MMPs like the MMP-2 have later peak  and gradually decrease at day 7. 
Matrix metalloproteinase 13 is a potent zinc-dependent proteolytic enzyme involved in the 
degradation of the extracellular matrix components such as collagen fibers, gelatin ecc. Its 
physiologic activity is not restricted to the ECM degradation but it is involved in the processing 
of cytokines, growth factors and adesion molecules. Besides its physiological role in tissue 
remodeling, embryogenesis and cell behavior regulation, the proteolytic function, and in 
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particular the collagenolytic activity of MMP-13 has been demonstrated crucial for the fibrosis 
resolution in rodent models of liver fibrosis15. Indeed, this pathology is characterized by an 
extensive deposition of type I and type III collagen fibrils synthesized by hepatic stellate cells. At 
the same time, MMP-13 is believed to promote the early stages of the inflammation that trigger 
this disease16.  The already available data on the activity of MMP-13 in rodent liver inflammation 
and fibrosis was the prompt to better investigate its role in the different steps of the pathology. 
Materials and methods 
Expression and purification of human MMP13 and MMP12 catalytic domain. The cDNA of 
proMMP13 (Leu20-Pro268) was cloned into the pET21 vector (Novagen) using Nde I and Xho I 
as restriction enzymes. One additional methionine at position 19 was present in the expressed 
product. The stabilized cat-MMP-13 F175D mutant and the catalytically inactive E223A were 
produced using the quick-change site-directed mutagenesis kit (Quiagen). The E. coli strain BL21 
Codon Plus cells, transformed with the above plasmid, were grown in LB medium at 310 K. The 
protein expression was induced during the exponential growth phase with 0.5 mM IPTG. The 
cells were harvested 3 hours after induction. After cells lysis, the inclusion bodies, containing 
proMMP13, were solubilized in 8 M urea; 20 mM Tris (pH 8.0). The protein was purified on the 
Hitrap Q column (Pharmacia) with a buffer containing 6 M urea; 20 mM Tris (pH 8.0). The 
elution was performed using a linear gradient of NaCl up to 0.6 M. The purified protein was then 
refolded  using multi-step dialysis against solutions containing 50 mM Tris (pH 7.2); 10 mM 
CaCl2; 0.1 mM ZnCl2; 0.3 M NaCl and decreasing concentrations of urea. The refolded protein 
was exchanged, by dialysis, against a buffer with 50 mM Tris (pH 7.2); 5 mM CaCl2; 0.1 mM 
ZnCl2; 0.3 M NaCl. The protein was concentrated at room temperature using an Amicon 
concentrator, up to about 30 μM. The active protein is left overnight in these conditions to allow 
the autoproteolysis of the prodomain. After addition of Acetohydroxamic acid (AHA) to a final 
concentration of 0.5 M, the catalytic domain of MMP13 (Tyr 104- Pro 268) was purified using 
size-exclusion chromatography with the buffer 50 mM Tris (pH 7.2); 5 mM CaCl2; 0.1 mM 
ZnCl2; 0.3 M NaCl, 0.2 M AHA and then concentrated using a Centriprep concentrator at 277 K 
up to 15 uM.  
Cloning, expression and purification of the catalytic domain of MMP12 (F171D mutant) has been 
previously described. The recombinant proteins were dialyzed against a saline solution 
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containing  5 mM CaCl2 and 0.1 mM ZnCl2 to prevent protein unfolding. The proteolytic activity 
of the proteins was assayed by a spectrofluorimeter using the fluorogenic peptide substrate Mca-
Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (Biomol Inc.). 
Animals and protocols. Male, 7 weeks-old,  Wistar rats of 250 g body weight, SD1 and 
SCID/CB17 mice of 25 g body weight were used for the experiments. All animals were fed with 
Good Laboratory Practice diet in pellets, were housed in plastic cages with a wire-mesh 
providing isolation from a hygienic bed and were exposed to a 12-hour, controlled light cycle. 
Experiments were performed in accordance with the institutional ethical guidelines.   
CCl4 was diluted 50% (vol/vol) in olive oil, and the solution was administered in a dose of 4 
mL/kg for rats and 1 ml/kg for mice. The animals were randomly divided into four groups: 
treated with CCl4 only; with MMP-13 only; with both CCl4 and MMP-13; and control group, 
treated with olive oil and physiologic solution.  
The animals were killed using diethyl ether anesthesia and terminally bled via cardiac puncture. 
Kidneys and livers were collected and fixed in 4% phosphate buffered formaldehyde or in 
methanol for 18–24 hours and embedded in paraffin, for further examinations.  
Tissue sections (4μm thick) were stained with H&E staining (Merck) for morphometric analysis 
or with Sirius Red for collagen staining. The latter were performed by a computerized video-
image analysis system.  
 
Results and discussion 
Besides the classical collagenolytic activity of MMP13, that has been demonstrated after fibrils 
deposition15, the proteolysis of other physiologically relevant substrates by MMP-13 may play a 
role in the inflammation process that is at the basis of liver fibrosis 16. The extensive 
vascularization of the liver together with its very high scavenger activity toward exogenous 
proteins such as trombolytic enzymes, therapeutic monoclonal antibody, ecc.,  render the liver a 
suitable target to evaluate the effect of their intravenous administration. In particular, 
parenchymal liver cells are responsible for most of the liver up take of the exogenous protein that 
are then degraded in the lysosomal compartment of these cells17. However, to properly evaluate 
the role of this poorly characterized proteolitic activity of MMP-13 in the pathological process of 
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liver fibrosis, it is important to design an experimental procedure to selectively abolish the 
collagenolityc properties of the protein, without affecting the enzymatic activity toward other 
substrates. 
It has been shown that Hemopexin domain is required for the degradation of the triple helix 
collagen, while the proteolytic activity toward peptides is usually retained by the isolated 
catalytic domain18,19. Therefore the use of the catalytic domain, instead of the whole enzyme in 
rodent models of liver inflammation and fibrosis, was selected to provide answers to several open 
questions about the molecular mechanisms that induce the pathology. In humans, the homologous 
MMP-1 more than MMP-13 seems to play a critical role in such pathological process. Hence, the 
human construct, instead of the murine MMP13, was chosen in order to investigate a possible 
different role of human MMP-13. 
At the concentrations required for the in vivo experiments, the wild type catalytic domain of 
MMP13 undergoes to a fast self-proteolysis. Therefore, samples of wild type catalytic domain of 
MMP-13 were investigated by MS-MALDI in order to identify the cleavage sites.  Two main 
fragments arise from the proteolytic cleavage of the protein at the peptidic bond between Asp 174 
and Phe 175. Therefore, the protein was stabilized by replacing the lypophilic Phe with one 
charged aminoacid (Asp) at  position 175.  This mutation is far from the active site and does not 
perturb the catalytic activity of the enzyme, as verified by spectrofluorimetric activity assay (data 
not shown). 
Lacking any information about the pharmacokinetic, pharmacodynamic and the in vivo activity of 
MMP-13, the therapeutic doses of thrombolytic enzymes were considered as reference to design 
the experiments. 
The evaluation of acute toxicity of recombinant human cat-MMP13 was carried out in 7 weeks 
old CD1 mice, weighing about 25 grams. Two doses of MMP13 were tested (1.4 mg/kg and 
2.8mg/kg corresponding to 100 and 200 μl of solution injected into the tail vein, respectively). 
Control mice were treated with 100 μl of physiologic saline solution. The animals were divided 
in 4 groups: non-treated mice (2 animals); control mice (3 animals) high dose-treated mice (3 
animals); low dose-treated mice (3 animals). The animals were injected at day 1 and day 3 and 
then were sacrificed 24 hours after the last injection. At the time of sacrifice, a macroscopic 
evaluation of internal organs was carried out. Livers and kidneys were harvested for further 
analysis. Serial sections of the collected tissues were stained with haematoxylin/eosin  and Sirius 
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Red, for the histological evaluation and for collagen analysis, respectively. The microscopic 
examination of the stained tissues showed that the administration of cat-MMP13 did not induce 
any evident alteration of the hepatic parenchyma at macroscopic and microscopic level at both 
administered doses. On the other hand, kidneys of animals treated with saline solution present a 
trend of increasing size of the clusters kidney, and an increase of capsules space compared to 
untreated mice. Same alterations were found in animals treated with cat-MMP13 (2.8mg/kg in 
200µl), but the glomerular structure was slightly changed compared to animals treated with 100µl 
of physiologic solution, that could be explained because the volume of cat-MMP13 was the 
double of the volume injected into the tail vein of the control mice. Hence, the observed 
alterations could be due to the volume of injected solution. Long term toxicity of the cat-MMP13 
treatment was not evaluated because of the strong possibility of antigenic response of the animals 
to the MMP-13 administration.  
Once the absence of toxic effect of human MMP-13 on mice was evaluated, the effects of the 
administration of MMP-13 by tail vein injection has been investigated in mouse and rat models 
of liver fibrosis.  
In order to establish the minimum efficacious dose of cat-MMP13 in the rat model, the 
recombinant protein was administered to a group of rats in a single dose of 0.08, 0.32, 1.4 and 2.8 
mg/kg  by tail vein injection, 6h after the intraperitoneal administration of 1 ml/kg of CCl4.  The 
animals were sacrificed 24, 48, 72, and 96 hours after the injection of the CCl4 and the livers 
were stained and examined. The histological evaluation of liver specimens from control and 
treated rats established significant differences related to the administration of MMP-13 and to its 
dosage. The administration of the protein significantly reduces the score for necrosis and 
inflammation of liver,  speed-up the recovery of liver parenchyma and reduces the infiltrate. The 
liver-protecting effect is dose-dependent and increase up to 1.4 mg/kg. The administration of a 
higher dose of MMP-13 (2.8 mg/kg) does not improve the activity. Then doses of 1 mg/kg for 
CCl4 and 1.4 mg/kg for cat-MMP13 were selected for animals administration. 
First, rats were used as model. Rats, of an average weight of 250 g, were splitted in 4 groups: 
treated with CCl4 only, with MMP-13 only, with both CCl4 and MMP-13; control group was 
treated with olive oil and physiologic solution. Six hours after the CCl4 intraperitoneal injection, 
MMP-13 was administered through the tail vein. All animals were sacrificed 24, 48, 72 hours 
after MMP13 injection and the liver tissues were harvested. Rats treated only with CCl4 
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presented the common pattern of alterations, with ballooning hepatocytes, necrotic areas and 
strong inflammatory infiltrations. The group treated with both CCl4 and MMP13, presented a 
reduced number of degenerating cells at 24 hours after MMP13 injection. At 48 and 72 hours 
there was as well a decreased alteration of the parenchymal structure of the liver, and there was a 
markedly reduced infiltration of inflammatory cells. Rats treated only with MMP-13 did not 
show any alteration in the liver in response to the protein, as previously observed in mice. Data 
obtained in rat model of liver fibrosis suggest a protective role of MMP13 in CCl4-induced acute 
inflammation. This effect is not related to the collagenolytic activity of the enzyme, but it may be 
due to its proteolytic activity on other substrates in the hepatic tissue.  
Following these findings, the effect of cat-MMP13 treatment was evaluated also in mice, that 
first underwent to a chronic treatment with CCl4. Males, 7 weeks-old SCID/CB17 mice, with an 
average body weight of 25g, were divided in 4 groups (6 animals each), as reported for rats. The 
treatment with CCl4 was twice a week for 4 weeks, followed by the injection of MMP-13 or 
saline solution, 6 hours after the last CCl4 injection. The initial doses and routes of administration 
tested were of 1 ml/kg of CCl4 and 1.4 mg/kg of cat-MMP13, but, due to the high mortality after 
only 1 week of treatment, the experiment was interrupted. The mortality was 33% (2/6) in the 
control group treated with only CCl4 and 50% (3/6) in the group treated with CCl4 and cat-
MMP13. At the macroscopic examination, both groups presented large necrotic areas in the liver 
contest. At the histological analysis, the massive hepatic damage induced by CCl4 administration 
did not show differences, compared to the control group. Then, due to the high toxicity of CCl4 in 
this mouse line, the CCl4 concentration was decreased. In the new experimental protocol, 8 
animals as control group, and 9 animals as treated group were used. 0.4 ml/kg of CCl4 was 
administered twice a week for 4 weeks. In control mice,  100 µl of physiologic saline solution 
was administered, 6 hours after the last CCl4 treatment, while in treated mice 1.4 mg/kg of human 
cat-MMP13 in 100 µl of physiologic solution were injected. The animals were weighted once a 
week before and after treatments. All animals were sacrificed 24 hours after treatment with 
MMP13. Then internal organs were macroscopically evaluated, and livers were collected for 
further biochemical analysis. At the time of explanation, body and liver weights were assessed. 
After 4 weeks of treatment the weight of the MMP13-treated group was significantly higher than 
controls (see table 1), but there was no difference in the ratio between the liver and the total body 
weight. 
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Table 1 Average body weight of mice, before and after treatment with CCl4 (A)  
and with CCl4 + MMP-13 (B). 
 
 
 
 
 
The histological analysis of liver from 3 animals of the control group, showed necrotic areas, 
while none of the animals treated with MMP13 had  such  alterations.  As  shown  by  Sirius  Red 
staining, the administration of cat-MMP13 does not completely block the CCl4-induced liver 
fibrotic process, especially in proximity of large vessels, anyway, it was able to reduce the 
amount of total collagen depositions and  the inflammatory process. 
To prove that the proteolytic mechanism of MMP13 is responsible for the observed anti-
inflammatory activity of cat-MMP13, the recombinant inactive mutant of the protein, obtained by 
replacing the catalytically relevant  glutamate 223 with alanine, was injected into a group of 
CCl4-treated animals following the same experimental protocol. The severity of liver 
inflammation was similar to that observed for the control group which had not received the 
protein. This experimental evidence supports the hypothesis that the proteolytic activity  of the 
catalytic domain of MMP13 is responsible for the observed fast recovery of liver parenchyma 
and anti-inflammatory activity.  
The specificity of catalytic activity of MMP13 on liver of animals, treated with CCl4, was 
verified by the evaluation of the effects of the catalytic domain of MMP12, administered 
following the same protocol in rats and mice. No protective effect of cat-MMP12 on the CCl4-
induced inflammatory process was observed.  
In conclusion, from our studies the acute administration of recombinant human cat-MMP13 is not 
toxic and does not induce, in  mouse and rat models, obvious changes in the liver. Only poorly 
significative alterations in the kidney are observed, most likely due to the rapid injection of a 
solution into the tail vein. No data are available on the chronic toxicity, because the proteic nature 
of the drug involves the risk of an immune response in the animal models.  
Data obtained from the treatment of mice and rats models of liver fibrosis induced by CCl4 
administration showed that the non-collagenolytic catalytic activity of MMP13 trigger a 
 A B p value 
Before 23±1.14 24,67±1.87 0.06 
After 23.96±1.34 26.13±1.53 0.01 
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protective role during the initial phases of liver fibrosis. In particular, cat-MMP13 plays a key 
role in the reduction of the inflammatory process, by reducing the amount of necrotic cells and 
inflammatory cells in the hepatic tissue. Even if our investigations do not reveal the molecular 
target of the proteolytic activity of MMP13, we can hypothesize that cytokines or adhesion 
molecules could be involved in this collagenolytic-independent process carried out by MMP13.  
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Figures and legends: 
 
 
 
 
 
Figure 1 Sirius red-Haematoxylin/eosin  staining of livers from CD1 mice. 
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Figure 2 Sirius red-Haematoxylin/eosin  staining of kidneys from CD1 mice treated with 1.4 
and 2.8 mg/kg of catMMP13. 
 
 
 
Figure 3 Sirius red-Haematoxylin/eosin  staining of livers from SCID mice treated with 1 
ml/kg of CCl4 and 1.4 mg/kg of cat-MMP13. 
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Figure 4 Sirius red-Haematoxylin/eosin  staining of livers from SCID mice untreated and 
treated with 0.4 ml/kg of CCl4 for 4 weeks. 
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Figure 5 Sirius red-Haematoxylin/eosin  staining of livers from SCID mice treated with 0.4 
ml/kg of CCl4 for 4 weeks  and then with 1.4 mg/kg of catMMP13. 
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I.  V. S100 Proteins Regulate p53 Oligomerization State 
 
 
 V.1. INTRODUCTION 
The p53 protein acts mainly as a transcription factor, although some apoptotic 
activities are transcriptionally independent. In response to genotoxic stress, p53 translocates 
in the nucleus where it can form the active homotetramer and then activate the expression of 
genes necessary to maintain genomic stability1-4.  
The activity of p53 is regulated at different levels, including post-translational modifications, 
p53 stability, localization and tetramerization5-12. Tetramerization is relevant for p53 activity 
at three cross-regulated levels: stability, cellular localization and DNA binding. Indeed, p53 
nuclear translocation is more effective for the monomeric form, moreover p53 tetramerization 
cover a NES signal, leading to nuclear retention. Localization is important also in the 
regulation of p53 stability, indeed nuclear p53 is ubiquitinated by MDM2 and ubiquitination 
contributes to its export in the cytoplasm, where it is degraded by a MDM2-mediated 
mechanism13. Finally, the binding of p53 to DNA is cooperative, with the dimer having less 
affinity for the DNA with respect to the tetramer, which is the active form of the transcription 
factor14. 
In more than 50% of all human cancers, the loss of p53 activity by mutations is a molecular 
key event in deregulation of cellular homeostasis and in the development of tumors15. 
Anyway, in a lot of cancer cells expressing wild type p53, inhibition of tumor suppressor 
activity has been found to be correlated with deregulation of proteins involved in modulation 
of p53 activity.  
Some members of the S100 family interact with p53, and they exert different effects on p53 
activity6. The most studied are S100A4 and S100B, which are thought to inhibit the 
phosphorylation of p53 C-terminal region, and p53 tetramerization, leading to inhibition of its 
transcriptional activity, thereby compromising p53 tumour-suppressor activity16-19. In 
contrast, S100A2 promotes p53 transcriptional activity20 and interestingly S100A4 has also 
been documented as enhancing p53-dependent apoptosis16. Thus the balance of actions of 
different S100 proteins within a cell will determine the function of p53.  
The binding properties of some S100 proteins with peptides derived from p53 has been 
characterized through different techniques, and these data suggest that different S100 proteins 
bind p53 in different ways, anyway only the p53-S100B complex has been characterised from 
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a structural point of view21-24. The binding of S100 proteins to p53 is dependent upon p53 
oligomerization state, post-translational modifications and peptide length. Moreover, S100 
proteins can bind different regions of p53 (NRD, TET domain, NLS), in particular, it has been 
proposed that S100s interacting with p53 NRD have a negatively charged hinge region 
(residues 45-51), while those that do not bind have a positive or null charge25.  
These binding properties could explain the observed different effects in the modulation of p53 
activity by some S100s, moreover the investigation of the interaction between S100 proteins 
and full length p53 could lead to some clarifications about the role of S100 proteins in the 
modulation of p53 activity. 
 
V.2. MATERIAL AND METHODS 
 P53 cDNA source. The human colorectal adenocarcinoma cell line SW620 (ATCC), 
expressing p53(R273H, P309S) mutant, was maintained in Dulbecco’s modified Eagle’s 
medium supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin and 10% foetal 
bovine serum in a humidified 5% CO2:95% air incubator at 37°. Total RNA was extracted 
from confluent cells with RNeasy Mini Kit (Qiagen), retrotranscribed with Omniscript 
Reverse Transcription kit (Qiagen) and cDNA was used as template for p53 cDNA 
amplification. 
 Cloning. Full length-, Δ93-, Δ292-p53 constructs were amplified by PCR from SW620 
cDNA, using specific primers for Gateway  Cloning System (Invitrogen) and cloned in 
different pDEST vectors, fused with N-terminal tags: 6xHis, GST, NusA, TrxA, MBP. 
P53Δ310 was cloned in pET15b vector (Novagen) in frame with the N-terminal 6xHis-tag, 
using NdeI and BamHI restriction sites. 
Mutagenesis. The wild type sequence (NM 000546) was obtained by H273R, S309P 
retromutations, and the M133L, V203A, N239Y, N268D mutations were inserted in the wild 
type sequence of full length- and Δ93-p53 to obtain the superstable mutant26. Mutagenesis  
reactions were performed with specific primers using the Quick Change Site-directed 
Mutagenesis kit (Stratagene). All sequences were verified. The full length p53 contains the 
P72R SNP (Ref SNP ID: rs1042522). 
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Recombinant proteins expression. All the fusion proteins were expressed in inclusion 
bodies in any tested conditions. The full length- and Δ93-p53 His tag fusion proteins were 
expressed in C41(DE3) E. coli strain. P53Δ292 and p53Δ310 were expressed in BL21-gold E. 
coli strain as His tag fusion proteins. Expression conditions were optimised for each 
construct. The proteins were extracted from inclusion bodies, purified by HisTag  affinity 
chromatography and refolded by dialysis. The refolded proteins were further purified by size 
exclusion chromatography. The protein folding was verified by 1D NMR spectroscopy. 
Light Scattering. The oligomerization state of concentrated samples of full length  p53 
was analysed by size exclusion chromatography and light scattering (Wyatt Technology). 100 
μl of samples containing increasing concentrations of full length p53 were loaded in a 
G2000SWXL analytical column (Tosoh Bioscience) with a void volume of 150 kDa. The 
column was connected to a multi-angle light scattering spectrometer. Data were analysed with  
Astra software (Wyatt Technology), to estimate the molar mass.  
NMR. 1H-15N HSQC and 1H-15N TROSY-HSQC spectra of 15N labelled S100A2 and 
S100P were acquired at 600 and 800 MHz, with and without unlabelled p53, either in 
presence and in absence of Ca2+ in 25mM Hepes, 150mM NaCl, 2mM DTT, pH 7.5. 
S100P-p53 interaction. His tagged full length p53 was immobilised on a His Gravitrap 
column (GE Healthcare) in 25mM Hepes, 150mM NaCl, 2mM DTT, pH 7.5, with and 
without 10 mM CaCl2. Untagged S100P was loaded on the column with and without 
immobilised p53, either in presence or absence of CaCl2. 
 
  V.3 RESULTS AND DISCUSSION 
P53 expression. The DNA sequence of p53 has been amplified using as template the 
cDNA retrotranscribed from the RNA extracted from a colon cancer cell line, SW620. This 
cell line has been chosen because normal cells have very low levels of p53 RNA and the 
amplification of p53 cDNA by PCR is impaired. On the contrary, SW620 cell line express 
high levels of p53(R273H, P309S) mutant and the wild type sequence can be easily obtained 
by retromutations. The recombinant expression of native full length p53 in E. coli is very 
difficult, because of the high molecular weight (180 kDa as tetramer), the presence of large 
unstructured regions both in the N-terminal and C-terminal of p53, the large number of Cys 
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residues, and the aggregation propensity. All the expression tests were conducted as reported 
in Table 1. 
All the constructs were expressed in inclusion bodies in any tested conditions, then only the 
His tag fusion protein was carried out for refolding. The yield of purified protein for the His 
tagged construct is 45-50 mg/L in LB growth medium. Refolding was carried out with a first 
dilution of denaturing agent (urea or Gnd-HCl), then with eight  steps dialysis to obtain the 
folded protein in 25 mM Sodium Phosphate buffer (pH 7.2), 150 mM NaCl, ZnCl2 0.1 mM, 
and 5 mM DTT. Zn2+ ions in the DBD are necessary for thermodynamic stability and reduce 
aggregation. The protein can be concentrated up to 0.2 mM, higher concentrations induce 
protein precipitation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The preparation of 15N labelled p53 was not possible, since in any tested conditions the 
protein was expressed but it was unable to refold. This problem in the preparation of labelled 
samples, impaired the possibility to carry out NMR experiments for the structural 
characterizations of FL-p53 in complex with S100 proteins. 
P53 aggregation was evaluated at different protein concentrations and buffer conditions, by 
size exclusion chromatography and multi-angle light scattering. P53 samples were loaded in a 
G4000SWXL analytical column (Tosoh Bioscience), with a void volume of 7000 kDa. The 
column was connected to a multi-angle light scattering spectrometer. The chromatogram in 
Fig. 1 shows the profile of UV absorbance and scattered light, obtained with a 200 μM sample 
of full length p53 in  25 mM HEPES, 150 mM NaCl, 2 mM DTT, pH 7.5. For higher 
concentration the amount of aggregates was higher and protein precipitation is induced. 
Table 1. 
EXPRESSION TESTS PARAMETERS 
Fusion tags HisTag / TrxA-HisTag / GST- 
HisTag / NusA-HisTag 
E. Coli strains BL21Gold – Origami – Rosetta pLysS  
C41(DE3) – BL21(DE3)Codon Plus RIPL 
Induction temperature 
(°C) 
37 – 30 – 25 – 18 
IPTG concentrations 
(mM) 
1 – 0.7 – 0.5 – 0.1 
Growth medium: LB – 2xYT – minimal medium (M9) 
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Fig. 1. Size exclusion and light scattering analysis of full length p53 aggregation. 
 
The interactions of S100 proteins with the pseudo wild type full length p53 were carried out 
by NMR spectroscopy using 15N S100 protein and unlabeled p53. 
 
P53-Apo-S100A2 interaction. Equimolar amounts of fl-p53 and apo-S100A2 were mixed at 1 
µM concentration in 25 mM HEPES, 150 mM NaCl, 2 mM DTT, pH 7.5, in order to prevent 
proteins precipitation. The sample was concentrated up to 0.1 mM.  
The sample of Ca2+-loaded S2100A2 and p53 was prepared by mixing apo proteins in diluted 
conditions and adding a concentrated solution of CaCl2 up to 1 mM, to obtain the holo 
sample. A partial precipitation occurred during concentration in presence of CaCl2, and the 
samples were clarified by centrifugation. 
As shown in Fig.2A, the 1H-15N HSQC spectrum of apo-15N S100A2 at 298 K was not 
affected by addiction of equimolar amount of p53, while in presence of CaCl2 (Fig. 2B) the 
1H-15N HSQC  spectrum of 15N S100A2 in presence of p53 was not detectable at 500 MHz, 
and only few chemical shifts were detected performing a CRINEPT-TROSY-1H-15N HSQC at 
higher temperature (308 K) with a 800 MHz spectrometer (Fig. 2C).  
These experiments confirmed that the interaction of S100A2 with p53 is Ca2+-dependent, but 
the quality of our acquisitions in these experimental conditions does not allow further 
structural characterizations. This can be due to partial proteins precipitation after mixing, that 
decrease the concentration of the sample, and to the formation of a high molecular weight 
215 kDa 
450 kDa 
 
700 kDa 
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complex. Also the concentration of the samples (around 0.1 mM) impaired the acquisition of 
NMR spectra of the complex. Higher concentrations did not improved the quality of the 
acquired NMR spectra because of proteins aggregation.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The interaction between p53 and S100A2 was observed also by agarose native gel 
electrophoresis. Samples were prepared as described for NMR experiments, and were 
analysed by native agarose gel electrophoresis. 1% agarose gel was prepared in buffer A (20 
mM HEPES, 19.2 mM Glycine, DTT 5 mM, pH 7.4) and the comb placed in the center of the 
Fig. 2. A:1H-15N HSQC spectra  of 0.1mM 
apo 15N S100A2  in 25mM HEPES, 
150mM NaCl, 2mM DTT, pH 7.5  at 298 
K with (green) and without (red) 0.1mM 
p53; B: 1H-15N HSQC spectrum  of 0.1mM 
15N S100A2  in 25mM HEPES, 150mM 
NaCl, 2mM DTT, 1 mM CaCl2 pH 7.5 at 
308 K; C: CRINEP-TROSY-1H-15N HSQC 
spectrum  of 0.1mM 15N S100A2  in 
25mM HEPES, 150mM NaCl, 2mM DTT, 
1 mM CaCl2 pH 7.5  with 0.1mM p53 at 
308 K. 
A 
B C
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gel. The gel was submerged in a reservoir containing Buffer A and electrophoresis was 
performed at a constant voltage of 50 V for 2 h at 4°C. As shown in Fig.3A, when p53 and 
S100A2 are mixed in presence of CaCl2, in the native gel a third band can be detected, which 
migrate toward the cathode. This band has been extracted from gel and loaded in SDS-PAGE, 
to demonstrate that it correspond to the complex between p53 and S100A2 (Fig. 3B).  
 
 
 
 
 
 
 
 
 
P53-S100P interaction. S100P is a member of S100 proteins, which has never been 
reported to interact with p53. The sequence analysis of  S100P, aligned with S100B and 
S100A4, which are reported to interact with p53, highlights slightly negative charge of loop 2 
at physiological pH. Also loop 2 of S100A4, which is reported to interact only with p53 TET 
domain, has the same charge at physiological pH. On the contrary, in S100B, like S100A1 
and S100A2, which are reported to interact with p53 NRD and TET domains, loop 2 has a net 
negative charge a physiological pH (Fig. 4). These data suggest that S100P should interact 
with p53 TET domain, but not with NRD. 
 
 
 
 
 
 
 
 
The interaction of S100P with FL-p53 was verified by agarose native gel, but the band 
corresponding to the complex cannot be detected in any tested conditions.     
Therefore, His GraviTrap column was used to evaluate the ability of untagged S100P to bind 
His tagged p53 immobilised on the column. The experiment were performed in 25 mM 
Fig. 4. Aminoacid sequences alignment of S100P with S100B and S100A4, with in evidence the residues of hinge 
(loop 2). Arrows indicate the residues of S100B involved in binding with p53 NRD as reported by Weber et al. 
 
Fig. 3. Analysis of complex formation of   
p53 and S100A2 by native gel electrophoresis and 
SDS-PAGE. 
S100A2 and p53 were incubated at a 1:1 molar 
ratio in 25 mM Hepes, 150 mM NaCl, 2 mM DTT, 
pH 7.5  for 1 hour at 4°C and centrifuged 5 min at 
14,000 g. The supernatants were loaded onto a 1 % 
native agarose gel (A) prepared in 20 mM HEPES, 
19.2 mM Glycine, DTT 5 mM, pH 7.4 . Lane 1, 
p53; lane 2, S100A2; lane 3, S100A2 and p53 (1:1 
molar ratio). Band C was extracted from gel and 
loaded in 15 % SDS-PAGE (B).
 1  2        3 
p53 
S100A2 
A
B
 ] Band C → SDS-PAGE
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HEPES, 150 mM NaCl, 2 mM DTT, pH 7.5 (buffer C) either in presence and in absence of 10 
mM CaCl2. Tagged p53 was immobilised in the column, loading the protein without Imidazol, 
and unbound protein was washed out with 40 mM Imidazol. Then untagged S100P was 
loaded in that column and its retention in the column was evaluated by washing with buffer C 
+ 40 mM Imidazol, and eluting the retained proteins with buffer C + 0.5 M Imidazol. 
As shown in Fig. 4, S100P is retained in the column only in presence of CaCl2 (Fig. 5A and 
B). In order to exclude possible interactions between the column and S100P in presence of 
CaCl2 and to demonstrate the Ca2+-dependent interaction with immobilised p53, S100P was 
loaded onto  His GraviTrap column without immobilised p53, in presence of 10 mM CaCl2 
(Fig. 5C). These experiments confirmed that S100P can bind p53 in presence of CaCl2. 
 
 
The interaction between p53 and S100P was evaluated also by NMR spectroscopy (Fig. 6). 
NMR samples were prepared as described for the interaction with S100A2. 1H-15N HSQC 
spectra of 15N S100P were performed with and without p53, in presence of 10 mM CaCl2 at 
700 MHz. In presence of p53, all peaks of 15N S100P disappeared, indicating the formation of 
higher molecular weight complex. 
These results prove that also S100P can bind p53 with a Ca2+-dependent mechanism and like 
the other S100 proteins could be involved in the regulation of p53 activity.  
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V.4.  PERSPECTIVES 
 
Structural information on S100s-p53 interactions will be acquired by NMR 
spectroscopy on the complex of S100 proteins with p53 C-terminal constructs (p53Δ292 and  
Δ310) in order to reduce the molecular weight of the complex and improve the NMR data. 
The superstable mutant full length p53 will be cloned in a modified a pRSETa plasmid with a 
N-terminally His-tagged lipoyl domain from Bacillus stearothermophilus dihydrolipoamide 
acetyltransferase (residues 1-87) which has been cloned by M. Allen and co-workers and 
allow the expression of soluble p53. 
 Fig. 6.  1H-15N HSQC spectrum 
of 0.1 mM 15N S100P in 25 mM 
HEPES, 150 mM NaCl, 2 mM 
DTT,  10 mM CaCl2, pH 7.5. 
The 1H-15N HSQC spectrum of 
0.1 mM  15N S100P after 
addiction of equimolar amount 
of unlabeled p53 acquired in the 
same conditions was empty. 
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VI. Characterization   of   CaM   targets    with   unknown   structures  
and  binding properties 
 
VI.1. Introduction 
Calmodulin  (CaM)  is  a CALcium MODULated proteIN, widely expressed in the 
cytoplasm of all higher eukaryotic cells and has been highly conserved through evolution. 
Calmodulin transduces signals to enzymes, ion channels and other proteins in response to 
variations of intracellular calcium levels. Calmodulin's target proteins come in various shapes, 
sizes and sequences and are involved in a lot of signal transduction pathways1-9.  
Tuberin is a 198 kDa  tumor suppressor protein containing 1807 amino acids and codified by 
tuberous sclerosis 2 gene(TSC2). Mutations in the TSC2 gene have been genetically linked to 
the  pathology of both tuberous clerosis disease (TSC) and lymphangioleiomyomatosis 
(LAM), classified as disorders of cellular migration,  proliferation, and differentiation10-12. 
The C terminal domain of tuberin has been reported to have GAP activity on Rheb small 
GTPase, involved in the mTOR signalling13-17, moreover it contains a CaM binding domain 
overlapped with the Estrogen Receptor α (ERα) binding domain. Moreover, in this domain a 
nuclear localization signal has been found to overlap to CaM/ERα binding domain18,19. 
Deletion mutagenesis studies suggested that mutations in CaM binding domain may be 
involved in the pathology of TSC and LAM.  
The CaM binding domains of most CaM target proteins are mainly random coil in solution, 
but adopt α-helical structures in the complex with CaM.  
A comparison of tuberin CaM binding domain with known CaM target peptides, has shown 
three conserved hydrophobic residues (W1740, L1744, I1747), aligned with the CaM binding 
peptide of plasma membrane Ca2+ pump. Unique among CaM targets, this Ca2+ pump can be 
activated by the C-terminal but not the N-terminal half of CaM20, suggesting a similar binding 
between CaM and tuberin. As CaM interacts with a variety of different target enzymes, the 
determination of structural differences between different CaM complexes is of great 
importance for the understanding of molecular recognition and specific signaling pathways. 
The interaction between CaM and tuberin has been studied in solution NMR, in order to 
obtain structural information on the complex. CaM N60D can selectively bind Ln3+ ions in 
place of Ca2+ in the second Ca2+-binding site of the N-terminal domain 21. Ln3+ ions were used 
to align the CaM-tuberin complex in a magnetic field and obtain information about the 
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flexibility of the  two domains of CaM in complex with tuberin, through analysis of NH 
residual dipolar couplings (RDCs). Indeed, if in the complex  the CaM domains are blocked, 
the RDC values are the same for N- and C-terminal domain, but if the two domain are flexible 
the RDC values for the C-terminal domain are smaller than those of the N-terminal domain.  
 
VI.2. Material and Methods 
CaM Targets screening. A list of six interesting human Calmodulin interacting 
proteins was obtained by searching in different databases. The coding sequences of selected 
CaM targets were cloned into different Gateway expression vectors and screened for 
expression and solubility in E. coli strains. Refolding trials were carried out for insoluble 
proteins.  
Tuberin expression. Tuberin (1531-1758) expression vector was transformed in  BL21 
(DE3) Gold E. coli strain (Novagen). Bacteria were grown at 37°C until OD600 of 0.8 was 
reached. The protein expression was induced by addiction of 0.5 mM IPTG. The cells were 
allowed to growth further at 18°C for 18-20 hours and then harvested by centrifugation.  
Soluble proteins were extracted by sonication in ice-cold lysis buffer (20 mM HEPES  pH 
7.4, 0.2 M KCl, 10 mM Imidazol, 1 mM TCEP , 1 mM Pefabloc). Clarified soluble extract 
was loaded onto Ni2+-loaded HiTrap Chelating column, and tuberin was eluted in 20 mM 
HEPES pH 7.4, 0.2 M KCl, 0.5 M Imidazol, 1 mM TCEP, 1 mM Pefabloc, 10 mM EDTA. 
Purified tuberin was concentrated and further purified by size exclusion chromatography. All 
purification steps were carried out at 4°C, and protein was never concentrated more than 0.4 
mM to avoid aggregation.  
Mutagenesis. A stop codon was inserted after the codon of  Ile1754, to remove the last 
four aminoacids (CEEA) of tuberin (1531-1758), using QuickChange Mutagenesis kit 
(Stratagene).  
Tuberin peptide. Synthetic peptide of Tuberin (1740-1754), corresponding to the CaM 
binding domain of tuberin was  obtained from Inbios s.r.l. The lyophilised powder was 
resuspensed  in 20 mM HEPES pH 7.4, 0.15 M KCl, 1 mM TCEP at the concentration of 10 
mg/ml and used for titration experiments with N60D CaM. 
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Samples preparation. 15N apo CaM N60D 1 mM in 20 mM HEPES, 150mM KCl, 1 
mM TCEP, pH 7.4, was titrated with CaCl2 solution to obtain the Ca4CaM form. The 
Ca3LnCaM N60D was obtained by titration with CaCl2 and LnCl3 solutions (Ln3+=Tb3+, Yb3+, 
Tm3+, Dy3+). Titration were followed by  1H-15N HSQC spectroscopy. 
 
NMR. Titrations of  15N Ca4CaM N60D with unlabeled tuberin (1531-1754) and 
(1740-1754) were followed by 1H-15N HSQC spectroscopy, at 700 MHz, at 298 K. One-bond 
1H-15N coupling constants were measured by using the IPAP method. RDCs values were 
calculated as the difference of the fitted 1JNH between Ca4- and Ca3Ln-CaM N60D. 
 
 VI.3 Results and Discussion 
Different constructs of six selected CaM targets were cloned with Gateway technology in five 
expression plasmids carrying different fusion tags: HRPAP20(1-175), CAMTA1 (1547-
1618), MAX (22-103), AKAP79 (1-103), (1-72) and (1-170), TUBERIN (1531-1758), 
RAB3A (18-186). Expression clones were transformed in BL21(DE3)gold, BL21(DE3) 
Codon Plus RIPL, Origami pLysS and BL21(DE3)C41 pRosetta E. coli strains for expression 
tests in LB growth medium. The recombinant proteins overexpression was induced with 0.1 
and 0.5 mM IPTG and carried out at 37°C and 18°C. Soluble and unsoluble fractions were 
collected after 3, 6 and 18 hours of induction and all the samples were analysed by SDS- 
PAGE. Eight constructs shown in Table 1 were selected for scale up and purification tests. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Expressed CaM targets.  
CaM target Fusion Tag Expression 
(Soluble-
Insoluble) 
CAMTA1 (1547-1618) GST S 
GST S MAX (22-103) 
No tag I 
AKAP79 (1-103) GST S 
No tag I TUBERIN (1531-
1758) His S 
HRPAP20 (1-175) His I 
 86
HRPAP20 was expressed with the highest yield (Fig. 1), but it was insoluble in any tested 
conditions. Different refolding protocols were tried, but the protein was not refolded. The 
GST tagged CAMTA1 and AKAP79 were not cleaved by TEV protease to remove the fusion 
tag and had a very low yield of expression, while purified GST tagged MAX precipitates 
when it reaches the concentration of 25 μM, maybe due to protein unfolding.NMR sample of 
tuberin (1531-1754) was obtained, even if partially degraded (Fig. 2).  
Different ways were tried to avoid such problem in tuberin constructs: very fast sample 
preparation,  different protease inhibitors, different purification conditions, cold-inducible 
vectors, but without results.  
 
 
 
 
 
 
 
 
 
 
 
 
Since tuberin loose the C-terminal CaM binding domain because of protease degradation, the 
(1531-1758) construct was cloned in  coexpression vectors with CaM, fused with  different 
fusion tags, in order to test its stability in presence of its partner protein that may protect 
tuberin from proteases.  
 
 
 
 
 
 
 
 
 
1 2     3   4      5    6      7      8
Fig. 1. His tagged HRPAP20 (1-175) 
expression and purification. Inclusion 
bodies extract after 6 h expression at 30°C 
in LB medium, and eluted by Ni2+-loaded 
HiTrap Chelating column  (lane 1), Size 
exclusion chromatography fractions in 
denaturing conditions (lanes 3-7), 
concentrated unfolded sample (lane 8). 
Fig. 2. His tagged Tuberin (1531-1758) expression and purification. 
A: soluble extract after 16 h expression at 18°C in LB medium 
(lane1), elution from His Tag Affinity Column (lane 2).B: Size 
exclusion chromatography fractions (lanes 1-4). C. Tuberin 
degradation, 3 days (lane 1) and 1 month (lane 2) after purification.  
A B 
C 
1        2 
A 
Fig. 3. Map of the pQLink vectors and construction of co-expression plasmids. (A) Map and genetic elements of all 
pQLink vectors. MCS: multiple cloning site, TEV: TEV protease cleavage site, term: transcription terminator, LINK1 
and 2: recombination sites. (B) Construction of a co-expression plasmid from two pQLink plasmids with  CaM and CaM 
target (HRPAP20 or Tuberin) cDNA inserts, respectively. 
B 
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Also HRPAP20 (1-175) was cloned in coexpression plasmids with CaM, in order to help 
HRPAP20 folding in presence of soluble CaM. Both tuberin and HRPAP20 were cloned in 
pQlinks plasmids as described by C. Scheich et al22, in this way each protein is transcribed by 
its own promoter, and not in a polycistronic mRNA, that lead to lower expression levels23. 
The cloning protocol is shown in Fig. 3. From the expression tests both tuberin and HRPAP20 
were insoluble and in some condition also CaM  was expressed in inclusion bodies with the 
partner protein. Then the His-tagged tuberin construct cloned in pDEST17A Gateway vector 
was used for further experiments. 
In order to have a lower amount of degraded protein, His tagged tuberin (1531-1758) was 
used for NMR experiments immediately after purifications, indeed during the digestion with 
TEV protease to remove the tag, the protein degradation was higher. The degradation of 
tuberin was monitored up to 1 month: after three days, the 50% of the proteins is degraded 
and in one month the protein is completely degraded (Fig.2C). Tuberin folding was verified 
by 1D NMR analysis and unlabeled samples were prepared for NMR experiments to test the 
interaction with CaM. The interaction with CaM was performed with 15N N60D CaM either 
in the apo and Ca4 form. 1H-15N HSQC spectra at 298 K of 0.1 mM 15N Ca4CaM N60D with 
and without unlabelled tuberin (1531-1758), were performed in a 700 MHz spectrometer with 
cryoprobe.   
 
 
 
 
 
Fig 4. 1H-15N HSQC spectra of Ca4CaM in presence of Tuberin (1531-1758) acqiored at 700MHz 
spectrometer at 298 K. Samples were prepared in 20mM HEPES pH 7.4, 0.2 M KCl, 1 mM TCEP 
with 10% 2H2O. In blue: 1H-15N HSQC spectrum of  0.1 mM 15N Ca4CaM without  Tuberin (1531-
1758). In red: TROSY-1H-15N HSQC spectrum of 0.1 mM 15N Ca4CaM with unlabelled Tuberin 
(1531-1758) at 1:4 molar ratio 
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The titration was performed in five steps, up to 1:4 molar ratio between CaM and tuberin 
respectively, calculated without considering tuberin degradation. Fig. 4 shows the 1H-15N 
HSQC spectrum at 298 K of 0.1 mM 15N Ca4CaM N60D without tuberin (1531-1758) and the 
TROSY-1H-15N HSQC spectrum of 0.1 mM 15N Ca4CaM N60D with unlabeled tuberin 
(1531-1758) at 1:4 molar ratio.  
All the samples were in 20 mM HEPES pH 7.4, 0.2 M KCl, 1 mM TCEP. TCEP was used to 
prevent tuberin aggregation induced by the formation of intermolecular disulfide bridges; 
TCEP is a reducing agent, more strong and stable than the widely used DTT.  During titration, 
some signals of 15N CaM shifted, and other were not detected, then TROSY-1H-15N HSQC 
spectra were acquired in order to obtain more signals in the spectra of CaM in complex with 
tuberin (Fig.4). The data show that CaM and tuberin interact, the exchange between the free 
and tuberin-bound CaM is fast, due to the interaction between the two proteins in the 
micromolar range. 
The CaM-tuberin complex was analysed in solution by NMR, with a paramagnetic lanthanide 
substituting the second calcium ion in the N-terminal domain of CaM. Lanthanide ions are 
used as probes to partially align the CaM molecules in the magnetic field, in order to calculate 
residual dipolar couplings (RDCs), and evaluate the orientation of the two proteins in the 
complex. Three different lanthanides were used to prepare Ca3LnCaM N60D (Ln= Tm, Tb, 
Yb). Ca3LnCaM samples were prepared with a titration of 25 mM CaCl2 in the solution of 
apo CaM, followed by 1H-15N HSQC spectroscopy, to obtain the Ca3 CaM form, then  LnCl3 
solutions were added to obtain the Ca3Ln CaM forms.  
The addiction of tuberin (1531-1758) to Ca3LnCaM induces shifting and widening of some 
signals of Ca3LnCaM. At the same time the addition of tuberin induce lost of paramagnetic 
signals in the spectrum of CaM. This can be due to the binding of  Ln3+ ions to two Glutamate 
residues present at the C-terminal of tuberin. To asses this hypothesis, a stop codon was 
inserted by site-directed mutagenesis after the codon of Isoleucine 1754, so removing the two 
glutamates from the construct. This new tuberin construct was expressed and prepared with 
the same protocol. Also the interaction of Ca3Ln CaM N60D with tuberin was performed in 
the same conditions. In this case the Ln ions remain bound to CaM. IPAP experiments were 
performed on 0.2 mM 15N N60D CaM in the Ca4 and Ca3Ln2+ forms (Ln = Tb, Yb, Tm) in 
presence of unlabelled 0.4 mM tuberin (1531-1754). RDCs were calculated as the difference 
of the fitted 1JNH between Ca3LnCaM and Ca4CaM, in presence of tuberin (1531-1754).  
Unfortunately, the large size of the complex that decrease the quality of acquired spectra, 
prevent a precise measurement of the RDC values. In order to obtain structural information on 
 89
the CaM-tuberin complex, a model peptide, corresponding to tuberin (1740-1754), was used 
to obtain structural information. First it was verified that both tuberin (1531-1754) and (1740-
1754) induce the same shifts in  15N Ca4CaM  1H-15N HSQC spectra.  
The binding of Ca4CaM to the tuberin peptide appears to be slightly stronger than that to 
tuberin (1531-1754). The estimated binding constant for Ca4CaM-peptide adduct was of the 
order of 20 μM. The binding of the tuberin peptide with apoCaM was also detected by NMR 
spectroscopy, through titration experiments, and a binding constant of about 450 μM has 
obtained. In fig. 5 the 1H-15N HSQC spectra of CaM, in the Apo- (fig. 5A) and Ca4-form, in 
presence of tuberin peptide, are shown (Fig. 5B).  
 
 
Fig. 5.  1H-15N HSQC spectra of CaM in presence of tuberin (1740-1754) sintetic peptide. (A) 
1H-15N HSQC spectrum of 0.45 mM 15N ApoCaM alone (in blue) and in presence of 1.6 mM 
unlabeled tuberin (1740-1754) (in red). (B) 1H-15N HSQC spectrum of 0.45 mM 15N Ca4CaM 
alone (in blue) and in presence of 1.1 mM unlabeled tuberin (1740-1754) (in red)  
 
The higher solubility of the tuberin peptide with respect to the protein allowed the acquisition 
of NMR spectra on more concentrated samples. 1H-15N HSQC (Fig. 6) and IPAP experiments 
were performed on 0.45 mM 15N Ca3Ln CaM in presence of 1.1 mM tuberin peptide (Ln=Tb, 
Yb, Tm, Dy). The lower molecular weight of the CaM-tuberin peptide complex  with respect 
to the CaM-tuberin (1531-1754) complex, provided a better spectra resolution, a RDC values 
could be obtained. The analysis of RDCs is still in progress. The experimental  RDC values 
has been used to obtain the magnetic susceptibility tensor for each paramagnetic metal ion, 
assuming the structural conformation of the N- and C- terminal domains of CaM as 
previously calculated for other CaM-peptide adducts. The magnetic susceptibility anisotropy 
Δχax and Δχrh were thus obtained for the CaM N-terminal and C-terminal domains separately, 
for the Tb and Tm ions, as shown in table 2. 
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Fig. 6. 1H-15N HSQC spectra of Ca3LnCaM in presence of tuberin (1740-1754) sintetic 
peptide. A: Ca3YbLnCaM; B: Ca3TbCaM; C: Ca3DyCaM. 
 
 
  Δχax  (m3) Δχrh (m3) 
N-terminal domain 4.4 ⋅10-31 1.2 ⋅10-31 Ca3TbCaM  
 C-terminal domain (residues from helices) 1.9 ⋅10-31 3.9 ⋅10-32 
N-terminal domain 2.2 ⋅10-31 3.9⋅10-31 Ca3TmCaM C-terminal domain (residues from helices) 1.4 ⋅10-31 7.1 ⋅10-31 
Table 2. Δχax and Δχrh values obtained for Ca3TbCaM and Ca3TmCaM in presence of tuberin 
peptide. 
 
The axial anisotropy values calculated for the Ca3LnCaM N-terminal were similar to the 
calues previously obtained for other EF-hand proteins in presence of the same lanthanides. 
The Δχax values obtained from the C-terminal helices residues, were, on the contrary, around 
2-3 times smaller, indicating some degree of mobility of the C-terminal domain, with respect 
to the N-terminal domain of CaM in complex with the tuberin peptide. 
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VII. SUMMARY AND PERSPECTIVES 
 
NMR spectroscopy and biophysical characterizations techniques, such as native gel 
electrophoresis, mass spectrometry, light scattering, have been used to characterise 
protein-protein complexes and mechanisms responsible for protein  function. 
The in vitro characterization of proteins and protein complexes is at the basis of structural 
studies, since, for these types of experiments, the proteins are not in physiological 
conditions and are required  at very high concentrations, hence, the best experimental 
conditions have to be found, according to the biophysical characteristics of the proteins.  
The in vivo study of recombinant protein function helps in the understanding of the 
physiologic role of a protein, which can be involved in different pathways and exert 
different functions on the basis of a physiological or pathological context. 
Therefore, it is clear that an integrated approach in the study of proteins function is 
essential, in order to obtain information on proteins and complexes from different 
techniques, that can provide different point of view on the function of proteins.  
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